0001140361-22-023089 | S-4 | XBRL Viewer | Caladrius Biosciences INC

Stock Options

Three Months Ended

March 31,

Total fair value of shares vested

Weighted average estimated fair value of shares granted

Print Document View Excel Document

Document and Entity Information	3 Months Ended
Document and Entity Information	Mar. 31, 2022
Cover [Abstract]
Document Type	S-4
Amendment Flag	false
Entity Registrant Name	CALADRIUS BIOSCIENCES, INC.
Entity Central Index Key	0000320017
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false

Consolidated Balance Sheets (FY) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Current Assets
Cash and cash equivalents	$ 12,747	$ 24,647		$ 16,512
Marketable securities	75,772	70,323		18,061
Prepaid and other current assets	2,181	1,212		758
Total current assets	90,700	96,182		35,331
Property and equipment, net	55	62		57
Other assets	708	764		614
Total assets	91,463	97,008		36,002
Liabilities
Accounts payable	697	1,934		1,020
Accrued liabilities	2,104	2,589		2,486
Total current liabilities	2,801	4,523		3,506
Other long-term liabilities	421	485		254
Total liabilities	3,222	5,008		3,760
Commitments and Contingencies
Stockholders' Equity
Preferred stock; authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 0.001 share of common stock, $0.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at December 31, 2021 and December 31, 2020, respectively	0	0		0
Common stock, $0.001 par value, authorized 500,000,000 shares; issued 59,800,792 and 19,389,413 shares, at December 31, 2021 and December 31, 2020, respectively; and outstanding, 59,789,712 and 19,378,333 shares, at December 31, 2021 and December 31, 2020, respectively	61	60		19
Additional paid-in capital	546,580	545,988		458,748
Treasury stock, at cost; 11,080 shares at December 31, 2021 and December 31, 2020 respectively	(708)	(708)		(708)
Accumulated deficit	(457,242)	(453,016)		(425,550)
Accumulated other comprehensive loss	(196)	(70)		(13)
Total Caladrius Biosciences, Inc. stockholders' equity	88,495	92,254		32,496
Non-controlling interests	(254)	(254)		(254)
Total stockholders' equity	88,241	92,000	$ 110,014	32,242	$ 20,553
Total liabilities, non-controlling interests and stockholders' equity	$ 91,463	$ 97,008		$ 36,002

Consolidated Balance Sheets (FY) (Parenthetical) - $ / shares	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Preferred Stock
Preferred stock, shares authorized (shares)	20,000,000	20,000,000	20,000,000
Preferred stock, liquidation preference (shares)	0.001	0.001	0.001
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01	$ 0.01
Preferred stock, shares designated (shares)	825,000	825,000	825,000
Preferred stock, shares issued (shares)	10,000	10,000	10,000
Preferred stock, shares outstanding (shares)	10,000	10,000	10,000
Common Stock
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized (shares)	500,000,000	500,000,000	500,000,000
Common stock, shares, issued (shares)	60,544,144	59,800,792	19,389,413
Common stock, shares, outstanding (shares)	60,533,064	59,789,712	19,378,333
Treasury Stock
Treasury stock (shares)	11,080	11,080	11,080

Consolidated Statements of Operations (FY) - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Operating Expenses:
Research and development	$ 17,680	$ 9,253
General and administrative	11,370	9,892
Total operating expenses	29,050	19,145
Operating loss	(29,050)	(19,145)
Other income (expense):
Investment income, net	151	132
Other expense, net	(75)	0
Total other (expense) income	76	132
Net loss before benefit from income taxes and noncontrolling interests	(28,974)	(19,013)
Benefit from income taxes	(1,508)	(10,872)
Net loss	(27,466)	(8,141)
Less - net income attributable to noncontrolling interests	0	9
Net loss attributable to Caladrius Biosciences, Inc. common stockholders	$ (27,466)	$ (8,150)
Basic and diluted loss per share:
Caladrius Biosciences, Inc. common shareholders - basic (in dollars per share)	$ (0.50)	$ (0.53)
Caladrius Biosciences, Inc. common shareholders - diluted (in dollars per share)	$ (0.50)	$ (0.53)
Weighted average common shares outstanding:
Basic shares	55,313	15,440
Diluted shares	55,313	15,440

Consolidated Statements of Comprehensive Loss (FY) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Statement of Comprehensive Income [Abstract]
Net loss	$ (27,466)	$ (8,141)
Other comprehensive loss:
Available for sale securities - net unrealized loss	(57)	(15)
Total other comprehensive loss	(57)	(15)
Comprehensive loss	(27,523)	(8,156)
Comprehensive income attributable to noncontrolling interests	0	9
Comprehensive loss attributable to Caladrius Biosciences, Inc. common stockholders	$ (27,523)	$ (8,165)

- Definition

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References + Details

- Definition

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References + Details

- Definition

Amount after tax and reclassification adjustments of other comprehensive income (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

+ Details

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 23: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 31: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

+ Details

Consolidated Statements of Equity (FY) - USD ($) $ in Thousands	Total	Total Caladrius Biosciences, Inc. Stockholders' Equity	Series B Convertible Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Treasury Stock	Non- Controlling Interest in Subsidiary
Beginning Balance (in shares) at Dec. 31, 2019			10,000	10,529,000
Beginning Balance at Dec. 31, 2019	$ 20,553	$ 20,816	$ 0	$ 11	$ 438,911	$ 2	$ (417,400)	$ (708)	$ (263)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(8,141)	(8,150)					(8,150)		9
Unrealized loss on marketable securities	(15)	(15)				(15)
Share-based compensation (in shares)				53,000
Share-based compensation	1,117	1,117		$ 0	1,117
Net proceeds from issuance of common stock and warrants (in shares)				8,807,000
Net proceeds from issuance of common stock and warrants	18,728	18,728		$ 8	18,720
Ending Balance (in shares) at Dec. 31, 2020			10,000	19,389,000
Ending Balance at Dec. 31, 2020	32,242	32,496	$ 0	$ 19	458,748	(13)	(425,550)	(708)	(254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(8,063)	(8,063)					(8,063)		0
Unrealized loss on marketable securities	(59)	(59)				(59)
Share-based compensation (in shares)				273,000
Share-based compensation	413	413			413
Net proceeds from issuance of common stock and warrants (in shares)				39,841,000
Net proceeds from issuance of common stock and warrants	85,457	85,457		$ 41	85,416
Proceeds from option exercises (in shares)				7,000
Proceeds from option exercises	24	24			24
Ending Balance (in shares) at Mar. 31, 2021			10,000	59,510,000
Ending Balance at Mar. 31, 2021	110,014	110,268	$ 0	$ 60	544,601	(72)	(433,613)	(708)	(254)
Beginning Balance (in shares) at Dec. 31, 2020			10,000	19,389,000
Beginning Balance at Dec. 31, 2020	32,242	32,496	$ 0	$ 19	458,748	(13)	(425,550)	(708)	(254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(27,466)	(27,466)					(27,466)		0
Unrealized loss on marketable securities	(57)	(57)				(57)
Share-based compensation (in shares)				517,000
Share-based compensation	1,757	1,757		$ 0	1,757
Net proceeds from issuance of common stock and warrants (in shares)				39,888,000
Net proceeds from issuance of common stock and warrants	$ 85,500	85,500		$ 41	85,459
Proceeds from option exercises (in shares)	7,250			7,000
Proceeds from option exercises	$ 24	24		$ 0	24
Ending Balance (in shares) at Dec. 31, 2021			10,000	59,801,000
Ending Balance at Dec. 31, 2021	92,000	92,254	$ 0	$ 60	545,988	(70)	(453,016)	(708)	(254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(4,226)	(4,226)					(4,226)		0
Unrealized loss on marketable securities	(126)	(126)				(126)
Share-based compensation (in shares)				743,000
Share-based compensation	$ 593	593		$ 1	592
Proceeds from option exercises (in shares)	0
Ending Balance (in shares) at Mar. 31, 2022			10,000	60,544,000
Ending Balance at Mar. 31, 2022	$ 88,241	$ 88,495	$ 0	$ 61	$ 546,580	$ (196)	$ (457,242)	$ (708)	$ (254)

Consolidated Statements of Cash Flows (FY) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net loss	$ (27,466)	$ (8,141)
Adjustments to reconcile net loss to net cash used in operating activities:
Equity-based compensation expense	2,005	1,265
Depreciation and amortization	55	63
Amortization/accretion on marketable securities	2,514	307
Changes in operating assets and liabilities:
Prepaid and other current assets	(453)	56
Other assets	(150)	466
Accounts payable, accrued liabilities and other liabilities	1,250	(2,839)
Net cash used in operating activities	(22,245)	(8,823)
Cash flows from investing activities:
Purchase of marketable securities	(179,775)	(34,799)
Sales of marketable securities	124,939	27,542
Purchases of property and equipment	(60)	(20)
Net cash used in investing activities	(54,896)	(7,277)
Cash flows from financing activities:
Proceeds from exercise of options	24	0
Tax withholding payments on net share settlement equity awards	(248)	(148)
Net proceeds from issuance of capital stock	85,500	18,728
Net cash (used in) provided by financing activities	85,276	18,580
Net (decrease) increase in cash and cash equivalents	8,135	2,480
Cash and cash equivalents at beginning of period	16,512	14,032
Cash and cash equivalents at end of period	24,647	16,512
Supplemental Disclosure of Cash Flow Information:
Interest	0	0
Taxes	$ 0	$ 0

Consolidated Balance Sheets (Q1) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
ASSETS
Cash and cash equivalents	$ 12,747	$ 24,647		$ 16,512
Marketable securities	75,772	70,323		18,061
Prepaid and other current assets	2,181	1,212		758
Total current assets	90,700	96,182		35,331
Property and equipment, net	55	62		57
Other assets	708	764		614
Total assets	91,463	97,008		36,002
Liabilities
Accounts payable	697	1,934		1,020
Accrued liabilities	2,104	2,589		2,486
Total current liabilities	2,801	4,523		3,506
Other long-term liabilities	421	485		254
Total liabilities	3,222	5,008		3,760
Commitments and Contingencies
Stockholders' Equity
Preferred stock, authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 0.001 share of common stock, $0.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at March 31, 2022 and December 31, 2021, respectively	0	0		0
Common stock, $0.001 par value, authorized 500,000,000 shares; issued 60,544,144 and 59,800,792 shares at March 31, 2022 and December 31, 2021, respectively; and outstanding, 60,533,064 and 59,789,712 shares at March 31, 2022 and December 31, 2021, respectively	61	60		19
Additional paid-in capital	546,580	545,988		458,748
Treasury stock, at cost; 11,080 shares at March 31, 2022 and December 31, 2021	(708)	(708)		(708)
Accumulated deficit	(457,242)	(453,016)		(425,550)
Accumulated other comprehensive loss	(196)	(70)		(13)
Total Caladrius Biosciences, Inc. stockholders' equity	88,495	92,254		32,496
Non-controlling interests	(254)	(254)		(254)
Total stockholders' equity	88,241	92,000	$ 110,014	32,242	$ 20,553
Total liabilities, non-controlling interests and stockholders' equity	$ 91,463	$ 97,008		$ 36,002

Consolidated Balance Sheets (Q1) (Parentheticals) - $ / shares	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Preferred stock, shares authorized	20,000,000	20,000,000	20,000,000
Preferred stock, liquidation value	0.001	0.001	0.001
Preferred stock, par value (in usd per share)	$ 0.01	$ 0.01	$ 0.01
Preferred stock, shares designated	825,000	825,000	825,000
Preferred stock, shares issued	10,000	10,000	10,000
Preferred stock, shares outstanding	10,000	10,000	10,000
Common stock, par value (in usd per share)	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000	500,000,000
Common stock, shares issued	60,544,144	59,800,792	19,389,413
Common stock, shares, outstanding	60,533,064	59,789,712	19,378,333
Treasury stock (shares)	11,080	11,080	11,080

Consolidated Statements of Operations (Q1) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Operating Expenses:
Research and development	$ 3,278	$ 5,076	$ 17,680	$ 9,253
General and administrative	3,342	3,010	11,370	9,892
Total operating expenses	6,620	8,086	29,050	19,145
Operating loss	(6,620)	(8,086)	(29,050)	(19,145)
Other income (expense):
Investment income, net	63	23	151	132
Other expense, net	(148)	0	(75)	0
Total other (expense) income	(85)	23	76	132
Net loss before benefit from income taxes and noncontrolling interests	(6,705)	(8,063)	(28,974)	(19,013)
Benefit from income taxes	(2,479)	0	(1,508)	(10,872)
Net loss attributable to Caladrius Biosciences, Inc. common stockholders	$ (4,226)	$ (8,063)	$ (27,466)	$ (8,150)
Basic and diluted loss per share
Caladrius Biosciences, Inc. common stockholders - basic (in usd per share)	$ (0.07)	$ (0.19)	$ (0.50)	$ (0.53)
Caladrius Biosciences, Inc. common stockholders - diluted (in usd per share)	$ (0.07)	$ (0.19)	$ (0.50)	$ (0.53)
Weighted average common shares outstanding
Basic shares	60,560	42,117	55,313	15,440
Diluted shares	60,560	42,117	55,313	15,440

Consolidated Statements of Comprehensive Loss (Q1) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Statement of Comprehensive Income [Abstract]
Net loss	$ (4,226)	$ (8,063)	$ (27,466)	$ (8,141)
Available for sale securities - net unrealized loss	(126)	(59)	(57)	(15)
Total other comprehensive loss	(126)	(59)	(57)	(15)
Comprehensive loss attributable to Caladrius Biosciences, Inc. common stockholders	$ (4,352)	$ (8,122)	$ (27,523)	$ (8,165)

- Definition

Amount after tax and reclassification adjustments of other comprehensive income (loss).

+ References

+ Details

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

+ Details

Consolidated Statements of Equity (Q1) - USD ($) $ in Thousands	Total	Total Caladrius Biosciences, Inc. Stockholders' Equity	Series B Convertible Preferred Stock	Common Stock	Additional Paid in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Treasury Stock	Non- Controlling Interest in Subsidiary
Beginning Balance (in shares) at Dec. 31, 2019			10,000	10,529,000
Beginning Balance at Dec. 31, 2019	$ 20,553	$ 20,816	$ 0	$ 11	$ 438,911	$ 2	$ (417,400)	$ (708)	$ (263)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(8,141)	(8,150)					(8,150)		9
Unrealized loss on marketable securities	(15)	(15)				(15)
Share-based compensation (in shares)				53,000
Share-based compensation	1,117	1,117		$ 0	1,117
Net proceeds from issuance of common stock and warrants (in shares)				8,807,000
Net proceeds from issuances of common stock and warrants	18,728	18,728		$ 8	18,720
Ending Balance (in shares) at Dec. 31, 2020			10,000	19,389,000
Ending Balance at Dec. 31, 2020	32,242	32,496	$ 0	$ 19	458,748	(13)	(425,550)	(708)	(254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(8,063)	(8,063)					(8,063)		0
Unrealized loss on marketable securities	(59)	(59)				(59)
Share-based compensation (in shares)				273,000
Share-based compensation	413	413			413
Net proceeds from issuance of common stock and warrants (in shares)				39,841,000
Net proceeds from issuances of common stock and warrants	85,457	85,457		$ 41	85,416
Proceeds from option exercises (in shares)				7,000
Proceeds from option exercises	24	24			24
Ending Balance (in shares) at Mar. 31, 2021			10,000	59,510,000
Ending Balance at Mar. 31, 2021	110,014	110,268	$ 0	$ 60	544,601	(72)	(433,613)	(708)	(254)
Beginning Balance (in shares) at Dec. 31, 2020			10,000	19,389,000
Beginning Balance at Dec. 31, 2020	32,242	32,496	$ 0	$ 19	458,748	(13)	(425,550)	(708)	(254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(27,466)	(27,466)					(27,466)		0
Unrealized loss on marketable securities	(57)	(57)				(57)
Share-based compensation (in shares)				517,000
Share-based compensation	1,757	1,757		$ 0	1,757
Net proceeds from issuance of common stock and warrants (in shares)				39,888,000
Net proceeds from issuances of common stock and warrants	$ 85,500	85,500		$ 41	85,459
Proceeds from option exercises (in shares)	7,250			7,000
Proceeds from option exercises	$ 24	24		$ 0	24
Ending Balance (in shares) at Dec. 31, 2021			10,000	59,801,000
Ending Balance at Dec. 31, 2021	92,000	92,254	$ 0	$ 60	545,988	(70)	(453,016)	(708)	(254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(4,226)	(4,226)					(4,226)		0
Unrealized loss on marketable securities	(126)	(126)				(126)
Share-based compensation (in shares)				743,000
Share-based compensation	$ 593	593		$ 1	592
Proceeds from option exercises (in shares)	0
Ending Balance (in shares) at Mar. 31, 2022			10,000	60,544,000
Ending Balance at Mar. 31, 2022	$ 88,241	$ 88,495	$ 0	$ 61	$ 546,580	$ (196)	$ (457,242)	$ (708)	$ (254)

Consolidated Statements of Cash Flows (Q1) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net loss	$ (4,226)	$ (8,063)	$ (27,466)	$ (8,141)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation	760	597	2,005	1,265
Depreciation and amortization	7	16	55	63
Accretion on marketable securities	515	323	2,514	307
Changes in operating assets and liabilities:
Prepaid and other current assets	(969)	(1,763)	(453)	56
Other assets	57	81	(150)	466
Accounts payable, accrued liabilities and other liabilities	(1,786)	834	1,250	(2,839)
Net cash used in operating activities	(5,642)	(7,975)	(22,245)	(8,823)
Cash flows from investing activities:
Purchase of marketable securities	(26,546)	(75,911)	(179,775)	(34,799)
Sale of marketable securities	20,456	10,821	124,939	27,542
Net cash used in investing activities	(6,090)	(65,090)	(54,896)	(7,277)
Cash flows from financing activities:
Proceeds from exercise of options	0	24	24	0
Tax withholding payments on net share settlement equity awards	(168)	(184)	(248)	(148)
Net proceeds from issuance of common stock	0	85,457	85,500	18,728
Net cash (used in) provided by financing activities	(168)	85,297	85,276	18,580
Net (decrease) increase in cash and cash equivalents	(11,900)	12,232	8,135	2,480
Cash and cash equivalents at beginning of period	24,647	16,512	16,512	14,032
Cash and cash equivalents at end of period	$ 12,747	$ 28,744	$ 24,647	$ 16,512

The Business (FY)

3 Months Ended

12 Months Ended

Mar. 31, 2022

Dec. 31, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

The Business

Note 1 – The Business

Overview

Caladrius Biosciences, Inc. (“we,” “us,” “our,” “Caladrius” or the “Company”) is a clinical-stage biopharmaceutical company dedicated to the development of treatments and reversal of severe diseases. The Company is developing what are intended to be first-in-class therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the growth of new microvasculature. Its technology is intended to leverage these cells to enable the body's natural repair mechanisms using formulations unique to each medical indication.

The Company's leadership team has decades of collective biopharmaceutical product development experience in a variety of therapeutic categories. Its goal is to develop and commercialize products that address important unmet medical needs based on a broad and versatile portfolio of candidates. The Company’s current product candidates include:

•	XOWNA^® (CLBS16), the subject of both a completed positive Phase 2a study (ESCaPE-CMD) and an ongoing follow on Phase 2b study (FREEDOM Trial) in the United States for the treatment of coronary microvascular dysfunction (“CMD”);

•

HONEDRA^® (CLBS12), recipient of SAKIGAKE designation pursuant to which early conditional approval in Japan for the treatment of critical limb ischemia (“CLI”) and Buerger’s disease is being sought based on the current results of a clinical trial executed in Japan. HONEDRA® was the recipient of orphan drug designation in March 2021 from the U.S. Food and Drug Administration (“FDA”) for Buerger's disease; and

•	CLBS201, the subject of a study designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for patients with chronic kidney disease related to type 2 diabetes (diabetic kidney disease or “DKD”).

•

On April 26, 2022, the Company and Cend Therapeutics, Inc., a Delaware corporation (“Cend”), entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, a wholly-owned subsidiary of Caladrius will merge with and into Cend, with Cend surviving as a wholly-owned subsidiary of the Company (the “Merger”), subject to the terms of the Merger Agreement and stockholder approval of the transaction. Under the exchange ratio formula, as of immediately after the Merger, the former Cend stockholders are expected to own approximately 50% of the outstanding shares of Caladrius Common Stock and the Company’s stockholders as of immediately prior to the Merger are expected to own approximately 50% of the outstanding shares of Caladrius Common Stock. The actual allocation will be subject to adjustment based on our net cash balance at the time of closing and the amount of any transaction expenses of Cend in excess of $250 thousand at the time of closing. See Note 12 below for more information regarding the Merger and related transactions.

Ischemic Repair (CD34 Cell Technology)

The CD34+ cell was discovered as a result of the deliberate search for a cell capable of stimulating the development and/or repair of blood vessels. All tissues in the body maintain their function by replacing cells over time. In addition to the maintenance function, the body must also be capable of building new blood vessels after injury. A CD34+ cell is an endothelial progenitor cell that has the ability to stimulate new blood vessel formation at the level of the microvasculature. No other native cell discovered to date has demonstrated this same capability.

of new microvasculature and thereby increase blood flow to the impacted area. The Company believes that a number of conditions caused by underlying ischemic injury can be improved through its CD34+ cell technology including but not limited to Buerger's disease, CLI, CMD, and DKD.

XOWNA^® for Treatment of Coronary Microvascular Dysfunction

In 2017, with the assistance of a $1.9 million grant from the National Institutes of Health (Award Number R44HL135889), the Company initiated its program for XOWNA^® for the treatment of CMD, a disease that afflicts as many as 1.6 million patients in the United States alone, with no current targeted treatment options. That study, the ESCaPE-CMD Trial, was a Phase 2a proof-of-concept open label study that enrolled patients at the Mayo Clinic in Rochester, MN and Cedars-Sinai Medical Center in Los Angeles, CA. Those data showed a positive therapeutic effect with a statistically significant improvement in angina frequency, coronary flow reserve, Canadian Cardiovascular Society Angina Class and Seattle Angina Questionnaire scores, as well as an acceptable safety profile. The full data set from that study was presented at the SCAI 2020 Scientific Sessions Virtual Conference on May 14, 2020 by Dr. Timothy Henry, FACC, of the Christ Hospital in Cincinnati, Ohio. In December 2020, the Company commenced enrollment in its Phase 2b FREEDOM Trial of XOWNA^®, a double-blind, randomized and placebo-controlled clinical trial designed to further evaluate the efficacy and safety of intracoronary artery delivery of autologous CD34+ cells in subjects with CMD and without obstructive coronary artery disease. While early enrollment proceeded to plan with the first patient treated in January 2021, the impact of the COVID-19 pandemic contributed to a general slowing of enrollment, including supply chain disruptions affecting the availability of qualified catheters used in the diagnosis of CMD and/or administration of XOWNA^®. Protocol amendments to the initial FREEDOM Trial protocol, as agreed to by the FDA, were implemented with the goal of enhancing breadth and speed of subject enrollment.

HONEDRA^® for Treatment of Critical Limb Ischemia

The Company's randomized, open-label, registration-eligible study of HONEDRA^® in Japan for the treatment of CLI and Buerger's disease has, to date, demonstrated positive trends in both safety and efficacy. The HONEDRA^® study's enrollment, however, has been significantly curtailed by the COVID-19 pandemic's impact in Japan, including the States of Emergency in Japan that have persisted for much of 2020 and 2021. Due to the significant and continued operational and financial burden incurred as a result of these COVID-19 delays, coupled with the unpredictability of the timing of site enrollment re-initiation, Caladrius suspended further enrollment and is focusing its efforts on consummating a partnership for the product in Japan. Such a partnership may become the basis for the completion of development and registration of HONEDRA^® in Japan and may include the completion of enrollment of the four remaining no-option CLI subjects stipulated in the original protocol, if necessary, and/or exploration of the possibility of submitting the existing data to Japan's Pharmaceuticals and Medical Devices Agency (“PMDA”) under Japan's regenerative medicine regulations, which allow for conditional approval of innovative regenerative medicine products. Despite receipt from FDA in March 2021 of orphan designation in the U.S. for CLBS12 as a potential treatment for Buerger's disease, based on a response from the FDA in October 2021 regarding a development plan for U.S. registration the Company decided not to pursue United States development in Buerger's disease at this time.

CLBS201 for Treatment of Diabetic Kidney Disease

Progressive kidney failure is associated with attrition of the microcirculation of the kidney. Pre-clinical studies in kidney disease and injury models have demonstrated that protection or replenishment of the microcirculation results in improved kidney function. Based on these observations, the Company has elected to move forward with a Phase 1b, open-label, proof-of-concept trial evaluating CLBS201 dosed via intra-renal artery injections in subjects with DKD. This protocol is expected to include six subjects in total with the first two subjects sequentially dosed and followed for a two-week safety observation period. Clearance by the independent Data Safety Monitoring Board (“DSMB”) overseeing the study will then permit the treatment of the next four patients, with all patients being followed for safety and therapeutic effect. A read-out of data will occur after at the six-month follow-up visit for all patients. A key criterion for continued development of CLBS201 will be its ability to demonstrate a therapeutic effect that will make it competitive in the field of DKD treatment, i.e., kidney function regeneration, as indicated by increased glomerular filtration rate. As announced recently, the Company has treated the first patient in the CLBS201 proof-of-concept study and targets treatment completion for all six subjects during the third quarter of 2022.

Additional Out-licensing Opportunities and Pipeline Diversification

The Company's broad intellectual property portfolio of cell therapy assets includes notable programs available for out-licensing in order to continue their clinical development. The Company's current long-term strategy focuses on advancing its therapies through development with the ultimate objective of obtaining market authorizations and entering commercialization, either alone or with partners, to provide treatment options to patients suffering from life-threatening medical conditions. The Company believes that it is well-positioned to realize potentially meaningful value increases within its own proprietary pipeline if it is successful in advancing its product candidates to their next significant development milestones.

In addition, the Company further desires to diversify its pipeline of development products candidates and is exploring a range of strategic transactions in furtherance of that goal. The Company has taken, and intends to continue to take, active steps to identify assets and/or companies for acquisition and/or partnership that would enhance and de-risk its current development portfolio. Such assets could target indications beyond cardiovascular disease as well as product categories outside of cell therapy. The range of possible transactions includes an acquisition, merger, business combination, in-license or other strategic transaction, any of which could result in the issuance of securities that could significantly dilute the shares of its existing stockholders. There can be no assurance that this exploration of strategic alternatives will result in Caladrius entering into or completing any transaction or that such transaction, if completed, will add to shareholder value.

Coronavirus Considerations

In December 2019, a novel strain of coronavirus (SARS-CoV-2), which causes COVID-19, was reported to have surfaced in China. In March 2020, the World Health Organization declared the outbreak of COVID-19 to be a pandemic, and the world's economies began to experience pronounced effects. Despite the FDA approval of multiple COVID-19 vaccines in late 2020, there remains uncertainty around the extent and duration of disruption and any future related financial impact cannot reasonably be estimated at this time. In response to the COVID-19 pandemic, the Company implemented a universal work from home policy as well as stringent social distancing and other hygiene policies for employees when they must be in the office. The Company's clinical study of HONEDRA^® in Japan has experienced significant delays in enrollment due to the States of Emergency in effect in Japan for most of 2020 2021 covering Tokyo and other regions in response to an increased number of COVID-19 infections. With the Company's expectation that COVID-19 in Japan would continue to impact negatively clinical site operations and enrollment of patients in the HONEDRA^® clinical trial, it elected to suspend trial enrollment, seek a development partner and consult with the Japanese regulatory authorities regarding the submission of patient data already accrued. Caladrius' phase 2b trial of XOWNA^® in the U.S. has also experienced delays in enrolling patients as a result of COVID-19.

Basis of Presentation

The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company’s financial position as of March 31, 2022, and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December 31, 2021 and 2020 included in our 2021 Form 10-K. Operating results for the three months ended March 31, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022.

Use of Estimates

assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining stock-based awards values. Accordingly, actual results could differ from those estimates and assumptions.

Principles of Consolidation

The Consolidated Financial Statements include the accounts of Caladrius Biosciences, Inc. and its wholly owned and majority owned subsidiaries and affiliates. All intercompany activities have been eliminated in consolidation.

Note 1 – The Business

OVERVIEW

The Company's leadership team has decades of collective biopharmaceutical development experience. Its goal is to develop and commercialize products that address important unmet medical needs based on a broad and versatile portfolio of candidates. The Company's current product candidates include:

•	XOWNA^® (CLBS16), the subject of both a completed positive Phase 2a study (ESCaPE-CMD) and an ongoing follow-on Phase 2b study (FREEDOM Trial) in the United States for the treatment of coronary microvascular dysfunction (“CMD”);

•

•	CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for patients with chronic kidney disease related to type 2 diabetes (diabetic kidney disease or “DKD”).

Ischemic Repair (CD34 Cell Technology)

The Company's proprietary cell technology using autologous (a patient’s own naturally occurring) CD34+ cells has led to the development of therapeutic product candidates designed to address diseases and conditions caused by ischemia. Ischemia occurs when the supply of oxygenated blood to healthy tissue is restricted or reduced. Through the administration of CD34+ cells, Caladrius seeks to promote the development and formation of new microvasculature and thereby increase blood flow to the impacted area. The Company believes that a number of conditions caused by underlying ischemic injury can be improved through its CD34+ cell technology including, but not limited to, Buerger's disease, CLI, CMD, and DKD.

XOWNA^® for Treatment of Coronary Microvascular Dysfunction

double-blind, randomized and placebo-controlled clinical trial designed to further evaluate the efficacy and safety of intracoronary artery delivery of autologous CD34+ cells in subjects with CMD and without obstructive coronary artery disease. While early enrollment proceeded to plan with the first patient treated in January 2021, the impact of the COVID-19 pandemic contributed to a general slowing of enrollment. Protocol amendments to the initial FREEDOM Trial protocol, as agreed to by the FDA, were implemented with the goal of enhancing breadth and speed of subject enrollment.

HONEDRA^® for Treatment of Critical Limb Ischemia

The Company's randomized, open-label, registration-eligible study of HONEDRA^® in Japan for the treatment of CLI and Buerger's disease has, to date, demonstrated positive trends in both safety and efficacy. The HONEDRA^® study's enrollment, however, has been significantly curtailed by the COVID-19 pandemic's impact in Japan, including the States of Emergency in Japan that have persisted for much of the past 18 months. Due to the significant and continued operational and financial burden incurred as a result of these COVID-19 delays, coupled with the unpredictability of the timing of site enrollment re-initiation, Caladrius suspended further enrollment and is focusing its efforts on consummating a partnership for the product in Japan. Such a partnership may become the basis for the completion of development and registration of HONEDRA^® in Japan and may include the completion of enrollment of the four remaining no-option CLI subjects stipulated in the original protocol, if necessary, and/or exploration of the possibility of submitting the existing data to Japan's Pharmaceuticals and Medical Devices Agency (“PMDA”) under Japan's regenerative medicine regulations, which allow for conditional approval of innovative regenerative medicine products. Despite receipt from FDA in March 2021 of orphan designation in the U.S. for CLBS12 as a potential treatment for Buerger's disease, based on a response from the FDA in October 2021 regarding a development plan for U.S. registration the Company decided not to pursue United States development in Buerger's disease at this time.

CLBS201 for Treatment of Diabetic Kidney Disease

Progressive kidney failure is associated with attrition of the microcirculation of the kidney. Pre-clinical studies in kidney disease and injury models have demonstrated that protection or replenishment of the microcirculation results in improved kidney function. Based on these observations, the Company has elected to move forward with a Phase 1, open-label, proof-of-concept trial evaluating CLBS201 dosed via intra-renal artery injections in subjects with DKD. This protocol, as approved by an Institutional Review Board (the “IRB”), is expected to include six subjects in total with the first two subjects sequentially dosed and followed for a two-week safety observation period. Clearance by the independent Data Safety Monitoring Board (“DSMB”) overseeing the study will then permit the treatment of the next four patients, with all patients being followed for safety and therapeutic effect. A read-out of data will occur after at the six-month follow-up visit for all patients. A key criterion for continued development of CLBS201 will be its ability to demonstrate a therapeutic effect that will make it competitive in the field of DKD treatment, i.e., kidney function regeneration, as indicated by increased glomerular filtration rate.

Additional Out-licensing Opportunities and Pipeline Diversification

In addition, the Company further desires to diversify its pipeline of development products candidates and is exploring a range of strategic transactions in furtherance of that goal. The Company has taken, and intends to continue to take, active steps to identify assets and/or companies for acquisition and/or partnership that would complement its current development programs and de-risk its overall development portfolio. Such assets potentially could target indications beyond cardiovascular disease as well as product categories outside of cell therapy. The range of possible transactions includes an acquisition, merger, business combination, in-license or other strategic transaction, any of which could result in the issuance of securities that could significantly dilute

the shares of its existing stockholders. There can be no assurance that this exploration of strategic alternatives will result in Caladrius entering into or completing any transaction or that such transaction, if completed, will add to shareholder value.

Coronavirus Considerations

In December 2019, a novel strain of coronavirus (SARS-CoV-2), which causes COVID-19, was reported to have surfaced in China. In March 2020, the World Health Organization declared the outbreak of COVID-19 to be a pandemic, and the world's economies began to experience pronounced effects. Despite the FDA approval of multiple COVID-19 vaccines in late 2020, there remains uncertainty around the extent and duration of disruption and any future related financial impact cannot reasonably be estimated at this time. In response to the COVID-19 pandemic, the Company implemented a universal work from home policy as well as stringent social distancing and other hygiene policies for employees when they must be in the office. The Company's clinical study of HONEDRA^® in Japan has experienced significant delays in enrollment due to the States of Emergency in effect in Japan for most of 2020 and re-implemented from January 7, 2021 through March 21, 2021 covering Tokyo and other regions in response to an increased number of COVID-19 infections. Due to reported increases in COVID-19 cases and a low rate of vaccination in Japan, States of Emergency were renewed on April 25, 2021 through May 11, 2021 and then re-implemented in Tokyo from July 12, 2021 through September 30, 2021. With the Company's expectation that

COVID-19 in Japan would continue to impact negatively enrollment of patients in the HONEDRA^® clinical trial, it elected to suspend trial enrollment, seek a development partner and consult with the Japanese regulatory authorities regarding the submission of patient data already accrued. Caladrius' phase 2b trial of XOWNA^® in the U.S. has also experienced delays in enrolling patients as a result of COVID-19.

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimate and assumptions in determining stock-based awards values. Accordingly, actual results could differ from those estimates and assumptions.

Principles of Consolidation

Summary of Significant Accounting Policies (FY)

3 Months Ended

12 Months Ended

Mar. 31, 2022

Dec. 31, 2021

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 2 – Summary of Significant Accounting Policies

In addition to the policies below, the Company's significant accounting policies are described in Note 2 of the Notes to Consolidated Financial Statements included in its 2021 Form 10-K. There were no changes to these policies during the three months ended March 31, 2022.

Concentration of Risks

The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States. Therefore, the Company is not exposed to any significant concentrations of credit risk from these financial instruments. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.

Share-Based Compensation

The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. Consultant awards are remeasured each reporting period through vesting. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. The fair value of the Company’s restricted stock and restricted stock units is based on the closing market price of the Company’s common stock on the date of grant.

Note 2 – Summary of Significant Accounting Policies

Cash and Cash Equivalents

Cash and cash equivalents include short-term, highly liquid, investments with maturities of ninety days or less when purchased.

Concentration of Risks

credit risk from these financial instruments. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.

Marketable Securities

The Company determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of the Company's marketable securities are considered as available-for-sale and carried at estimated fair values and reported in cash equivalents and marketable securities. Unrealized gains and losses on available-for-sale securities are excluded from net income and reported in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Other income (expense), net, includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and other-than-temporary declines in the fair value of securities, if any. The cost of securities sold is based on the specific identification method. The Company regularly reviews all of its investments for other-than-temporary declines in fair value. The Company's review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether the Company has the intent to sell the securities and whether it is more likely than not that it will be required to sell the securities before the recovery of their amortized cost basis. When the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other-than-temporary, it reduces the carrying value of the security it holds and records a loss for the amount of such decline.

Property and Equipment

The cost of property and equipment is depreciated over the estimated useful lives of the related assets. Depreciation is computed on the straight-line method. Repairs and maintenance expenditures that do not extend original asset lives are charged to expense as incurred. The estimated useful lives of property and equipment are as follows:

Furniture and fixtures			10 years
Computer equipment			3 years
Software			3 years
Leasehold improvements			Life of lease

Long-lived Assets

Long-lived assets consist of property and equipment. The assets are amortized on a straight line basis over their respective useful lives. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds the fair value of the asset. If other events or changes in circumstances indicate that the carrying amount of an asset that the Company expects to hold and use may not be recoverable, the Company will estimate the undiscounted future cash flows expected to result from the use of the asset and/or its eventual disposition, and recognize an impairment loss, if any. The impairment loss, if determined to be necessary, would be measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.

Share-Based Compensation

The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. Consultant awards are remeasured each reporting period through vesting. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. Stock based compensation expense also includes an estimate, which is made at the time of the grant, of the number of awards that are expected to be forfeited. The fair value of the Company’s restricted stock and restricted stock units is based on the closing market price of the Company’s common stock on the date of grant.

Loss Per Share

Basic loss per share is based on the weighted effect of all common shares issued and outstanding and is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period. Diluted loss per share is calculated by dividing net loss attributable to common stockholders by the weighted average number of common shares used in the basic loss per share calculation plus the number of common shares that would be issued assuming conversion of all potentially dilutive securities outstanding. Diluted loss per share is not presented as such potentially dilutive securities are anti-dilutive to losses incurred in all periods presented.

Treasury Stock

Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Gains or losses on the subsequent reissuance of shares are credited or charged to additional paid in capital.

Research and Development Costs

Research and development (“R&D”) expenses include salaries, benefits, and other headcount related costs, clinical trial and related clinical manufacturing costs, contract and other outside service fees including sponsored research agreements, and facilities and overhead costs. The Company expenses the costs associated with research and development activities when incurred.

To further drive the Company’s cell therapy initiatives, the Company will continue targeting key governmental agencies, congressional committees and not-for-profit organizations to contribute funds for the Company’s research and development programs. The Company accounts for such grants as a deduction to the related expense in research and development operating expenses when earned.

New Accounting Pronouncements

In October 2019, the FASB issued ASU 2019-12, which affects general principles within Topic 740, Income Taxes. The amendments of ASU 2019-12 are meant to simplify and reduce the cost of accounting for income taxes. For public business entities, the amendments in this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. The Company believes that the adoption of this new accounting guidance has not had a material impact on its financial statements and footnote disclosures.

Available-for-Sale-Securities (FY)

3 Months Ended

12 Months Ended

Mar. 31, 2022

Dec. 31, 2021

Investments, Debt and Equity Securities [Abstract]

Available-for-Sale-Securities

Note 3 – Available-for-Sale-Securities

The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):

	March 31, 2022				December 31, 2021
	Cost	Gross Unrealized Gains	Gross Unrealized Losses	Estimated Fair Value	Cost	Gross Unrealized Gains	Gross Unrealized Losses	Estimated Fair Value
Corporate debt securities	$62,770	$—	$(162)	$62,608	$53,135	$—	$(65)	$53,070
Money market funds	6,578	—	—	6,578	18,124	—	—	18,124
Municipal debt securities	17,267	—	(34)	17,233	20,263	—	(5)	20,258
Total	$86,615	$—	$(196)	$86,419	$91,522	$—	$(70)	$91,452

Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale securities in our Consolidated Balance Sheets (in thousands):

	March 31, 2022	December 31, 2021
Cash equivalents	$10,647	$21,129
Marketable securities	75,772	70,323
Total	$86,419	$91,452

The following table summarizes our portfolio of available-for-sale securities by contractual maturity (in thousands):

	March 31, 2022
	Amortized Cost	Estimated Fair Value
Less than one year	$86,615	$86,419
Greater than one year		—
Total	$86,615	$86,419

Note 3 – Available-for-Sale-Securities

The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or debt marketable securities in the Company's Consolidated Balance Sheets (in thousands):

	December 31, 2021				December 31, 2020
	Cost	Gross Unrealized Gains	Gross Unrealized Losses	Estimated Fair Value	Cost	Gross Unrealized Gains	Gross Unrealized Losses	Estimated Fair Value
Corporate debt securities	$53,135	$—	$(65)	$53,070	$8,406	$—	$(7)	$8,399
Money market funds	18,124	—	—	18,124	7,591	—	—	7,591
Municipal debt securities	20,263	—	(5)	20,258	14,753	—	(6)	14,747
Total	$91,522	$—	$(70)	$91,452	$30,750	$—	$(13)	$30,737

Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale debt securities on the Company's Consolidated Balance Sheets (in thousands):

	December 31, 2021	December 31, 2020
Cash and cash equivalents	$21,129	$12,676
Marketable securities	70,323	18,061
Total	$91,452	$30,737

The following table summarizes the Company's portfolio of available-for-sale securities by contractual maturity (in thousands):

	December 31, 2021		December 31, 2020
	Amortized Cost	Estimated Fair Value	Amortized Cost	Estimated Fair Value
Less than one year	$91,522	$91,452	$30,750	$30,737
Greater than one year	—	—	—	—
Total	$91,522	$91,452	$30,750	$30,737

Property and Equipment (FY)

12 Months Ended

Dec. 31, 2021

Property, Plant and Equipment [Abstract]

Property and Equipment

Note 4 – Property and Equipment

Property and equipment consisted of the following (in thousands):

	December 31,
	2021	2020
Furniture and fixtures	$26	$26
Computer equipment	314	254
Leasehold improvements	90	90
Property and equipment, gross	430	370
Accumulated depreciation	(368)	(313)
Property and equipment, net	$62	$57

The Company’s results included depreciation expense of approximately $0.1 million and $0.1 million for the years ended December 31, 2021 and 2020, respectively.

Loss Per Share (FY)

3 Months Ended

12 Months Ended

Mar. 31, 2022

Dec. 31, 2021

Earnings Per Share [Abstract]

Loss Per Share

Note 4 – Income (Loss) Per Share

For the three months ended March 31, 2022 and 2021, the Company incurred net losses and therefore no common stock equivalents were utilized in the calculation of diluted loss per share as they are anti-dilutive. At March 31, 2022 and 2021, the Company excluded the following potentially dilutive securities (in thousands):

	March 31,
	2022	2021
Stock Options	2,640	1,022
Warrants	21,357	21,357
Restricted Stock Units	1,460	798

Note 5 – Loss Per Share

For the years ended December 31, 2021 and 2020, the Company incurred net losses and therefore no common stock equivalents were utilized in the calculation of loss per share as they are anti-dilutive in the periods presented. At December 31, 2021 and 2020, the Company excluded the following potentially dilutive securities (in thousands):

	December 31,
	2021	2020
Stock Options	2,132	964
Warrants	21,357	2,638
Restricted Stock Units	604	340

Fair Value Measurements (FY)

3 Months Ended

12 Months Ended

Mar. 31, 2022

Dec. 31, 2021

Fair Value Disclosures [Abstract]

Fair Value Measurements

Note 5 – Fair Value Measurements

The fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories:

Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.

Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.

Level 3 inputs are defined as unobservable inputs for the assets or liabilities. Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.

The following table sets forth by level within the fair value hierarchy the Company's financial assets that were accounted for at fair value on a recurring basis as of March 31, 2022 and December 31, 2021 (in thousands).

	March 31, 2022				December 31, 2021
	Level 1	Level 2	Level 3	Total	Level 1	Level 2	Level 3	Total
Assets:
Marketable securities - available for sale	$—	$75,772	$—	$75,772	$—	$70,323	$—	$70,323
	$—	$75,772	$—	$75,772	$—	$70,323	$—	$70,323

Note 6 – Fair Value Measurements

Fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories:

Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.

Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.

The Company's financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2021 and December 31, 2020 were as follows (in thousands):

	December 31, 2021				December 31, 2020
	Level 1	Level 2	Level 3	Total	Level 1	Level 2	Level 3	Total
Assets:
Marketable securities - available for sale	$—	$70,323	$—	$70,323	$—	$18,061	$—	$18,061
	$—	$70,323	$—	$70,323	$—	$18,061	$—	$18,061

The carrying values of cash, cash equivalents, accounts payable and accrued expenses approximate fair value at December 31, 2021 and December 31, 2020, due to the short maturity nature of these items.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Accrued Liabilities (FY)

3 Months Ended

12 Months Ended

Mar. 31, 2022

Dec. 31, 2021

Accrued Liabilities [Abstract]

Accrued Liabilities

Note 6 – Accrued Liabilities

Accrued liabilities as of March 31, 2022 and December 31, 2021 were as follows (in thousands):

	March 31, 2022	December 31, 2021
Salaries, employee benefits and related taxes	$1,005	$2,034
Operating lease liabilities — current	205	229
Other	894	326
Total	$2,104	$2,589

Note 7 – Accrued Liabilities

Accrued liabilities were as follow (in thousands):

	December 31,
	2021	2020
Salaries, employee benefits and related taxes	$2,034	$1,716
Operating lease liabilities - current	229	370
Other	326	400
	$2,589	$2,486

Operating Leases (FY)

3 Months Ended

12 Months Ended

Mar. 31, 2022

Dec. 31, 2021

Leases [Abstract]

Operating Leases

Note 7 – Operating Leases

The Company has operating leases for two offices with terms that expire in 2023 and 2025, respectively. The Company estimates its incremental borrowing rate at lease commencement to determine the present value of lease payments as most of the Company's leases do not provide an implicit rate of return. The Company recognizes lease expense on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of Topic 842, the Company elected to account for non-lease components associated with its leases and lease components as a single lease component. Each of the Company's leases includes options for the Company to extend the lease term and/or sub-lease space in whole or in part.

Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet were as follows (in thousands):

	March 31, 2022	December 31, 2021
Right-of Use Assets:
Other assets	$667	$724
Total Right-of-Use Asset	$667	$724

Operating Lease Liabilities:
Accrued liabilities	$205	$229
Other long-term liabilities	421	485
Total Operating Lease Liabilities	$626	$714

As of March 31, 2022, the weighted average remaining lease term for our operating leases was 2.3 years, and the weighted average discount rate for our operating leases was 9.625%. Future minimum lease payments under the lease agreements as of March 31, 2022 were as follows (in thousands):

Years ended			Operating Leases
2022			181
2023			217
2024			190
2025			143
Total lease payments			731
Less: Amounts representing interest			(105)
Present value of lease liabilities			$626

Note 8 – Operating Leases

The Company adopted ASU No. 2016-02, Leases (Topic 842) on January 1, 2019 and recognized leases with duration greater than 12 months on the balance sheet using the modified retrospective approach. The Company has operating leases for two offices with terms that expire in 2023 and 2025, respectively. The Company estimates its incremental borrowing rate at lease commencement to determine the present value of lease payments as most of the Company's leases do not provide an implicit rate of return. The Company recognizes lease expense on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of Topic 842, the Company elected to account for non-lease components associated with its leases and lease components as a single lease component. Each of the Company's leases includes options for the Company to extend the lease term and/or sub-lease space in whole or in part.

Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet as follows (in thousands):

	December 31, 2021	December 31, 2020
Right-of Use Assets:
Other assets	$724	$574
Total Right-of-Use Asset	$724	$574

Operating Lease Liabilities:
Accrued liabilities	$229	$370
Other long-term liabilities	485	254
Total Operating Lease Liabilities	$714	$624

As of December 31, 2021, the weighted average remaining lease term for our operating leases was 2.50 years, and the weighted average discount rate for our operating leases was 9.625%. Future minimum lease payments under the lease agreements as of December 31, 2021 were as follows (in thousands):

Years ended			Operating Leases
2022			$286
2023			217
2024			190
2025			143
Total lease payments			836
Less: Amounts representing interest			(122)
Present value of lease liabilities			$714

Stockholders' Equity (FY)

3 Months Ended

12 Months Ended

Mar. 31, 2022

Dec. 31, 2021

Equity [Abstract]

Stockholders' Equity

Note 8 – Stockholders' Equity

Equity Issuances

Purchase Agreement

In March 2019, the Company and Lincoln Park Capital Fund, LLC (“Lincoln Park”) entered into a purchase agreement (the “Purchase Agreement”) and a registration rights agreement (the “Registration Rights Agreement”), pursuant to which the Company has the right to sell to Lincoln Park shares of the Company’s common stock having an aggregate value of up to $26.0 million, subject to certain limitations and conditions set forth in the Purchase Agreement (the “Offering”). As consideration for entering into the Purchase Agreement, the Company issued to Lincoln Park an additional 181,510 shares of common stock as commitment shares.

Pursuant to the Purchase Agreement, Lincoln Park purchased 250,000 shares of common stock, at a price of $4.00 per share, for a total gross purchase price of $1.0 million (the “Initial Purchase”) upon commencement. Thereafter, as often as every business day from and after one business day following the date of the Initial Purchase and over the 36-month term of the Purchase Agreement the Company has the right, from time to time, at its sole discretion and subject to certain conditions, to direct Lincoln Park to purchase up to 100,000 shares of common stock, with such amount increasing as the closing sale price of the common stock increases; provided Lincoln Park’s obligation under any single such purchase will not exceed $2.5 million, unless the Company and Lincoln Park mutually agree to increase the maximum amount of such single purchase (each, a “Regular Purchase”). If the Company directs Lincoln Park to purchase the maximum number of shares of common stock it then may sell in a Regular Purchase, then in addition to such Regular Purchase, and subject to certain conditions and limitations in the Purchase Agreement, the Company may direct Lincoln Park in an “accelerated purchase” to purchase an additional amount of common stock that may not exceed the lesser of (i) 300% the number of shares purchased pursuant to the corresponding Regular Purchase or (ii) 30% of the total number of shares of the Company’s common stock traded during a specified period on the applicable purchase date as set forth in the Purchase Agreement. Under certain circumstances and in accordance with the Purchase Agreement, the Company may direct Lincoln Park to purchase shares in multiple accelerated purchases on the same trading day.

The Company controls the timing and amount of any sales of its common stock to Lincoln Park. There is no upper limit on the price per share that Lincoln Park must pay for its common stock under the Purchase Agreement, but in no event will shares be sold to Lincoln Park on a day the closing price is less than the floor price specified in the Purchase Agreement. In all instances, the Company may not sell shares of its common stock to Lincoln Park under the purchase agreement if it would result in Lincoln Park beneficially owning more than 9.99% of its common stock.

The Purchase Agreement does not limit the Company’s ability to raise capital from other sources at the Company’s sole discretion, except that (subject to certain exceptions) the Company may not enter into any Variable Rate Transaction (as defined in the Purchase Agreement, including the issuance of any floating conversion rate or variable priced equity-like securities) during the 36 months after the date of the Purchase Agreement. The Company has the right to terminate the Purchase Agreement at any time, at no cost to the Company.

As of March 31, 2022, the Company had not made any sales of common stock to Lincoln Park under the Purchase Agreement other than the Initial Purchase. The agreement expired on April 1, 2022.

At The Market Offering Agreement

On June 4, 2021, the Company entered into an At The Market Offering Agreement (the “ATM Agreement”) with HCW, as sales agent, in connection with an “at the market offering” under which the Company from time to time may offer and sell shares of its common stock, having an aggregate offering price of up to $50.0 million. During the three months ended March 31, 2022 and since inception the Company had not issued any shares under the ATM Agreement. Having received a listing deficiency notice from Nasdaq on February 18, 2022 after the Company’s shares traded below $1.00 for 30 consecutive trading days, the Company will not be permitted to sell additional shares under the ATM Agreement until it re-establishes timely compliance. Compliance may be reestablished by various mechanisms, including stock price appreciation at or above $1.00 for a requisite period of time and reverse stock split.

Stock Options and Warrants

The following table summarizes the activity for stock options and warrants for the three months ended March 31, 2022:

	Stock Options				Warrants
	Shares	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)	Shares	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)
Outstanding at December 31, 2021	2,131,849	$5.64	7.97	$—	21,356,600	$2.84	4.37	$—

Changes during the period:
Granted	540,600	0.91			—	—
Exercised	—	—			—	—
Forfeited	(9,565)	1.90			—	—
Expired	(23,275)	26.00			—	—
Outstanding at March 31, 2022	2,639,609	$4.51	7.83	$—	21,356,600	$2.84	4.13	$—
Vested at March 31, 2022 or expected to vest in the future	2,594,630	$4.57	7.80	$—	21,356,600	$2.84	4.13	$—
Vested at March 31, 2022	1,408,083	$7.36	6.41	$—	21,356,600	$2.84	4.13	$—

Restricted Stock

During the three months ended March 31, 2022 and 2021, the Company issued restricted stock for services as follows ($ in thousands):

	Three Months Ended March 31,
	2022	2021
Number of restricted stock issued	1,061,175	300,450
Value of restricted stock issued	$973	$478

The vesting terms of restricted stock issuances are generally between one to four years.

Restricted Stock Units

During the three months ended March 31, 2022 and 2021, the Company issued restricted stock units for services as follows ($ in thousands, except share data):

	Three Months Ended March 31,
	2022	2021
Number of restricted stock units issued	1,379,860	458,245
Value of restricted stock units issued	$1,265	$729

The weighted average estimated fair value of restricted stock issued for services in the three months ended March 31, 2022 and 2021 was $0.92 and $1.59 per share, respectively. The fair value of the restricted stock units was determined using the Company’s closing stock price on the date of issuance. The vesting terms of restricted stock unit issuances are generally one year, or upon the achievement of performance-based milestones.

Note 9 – Stockholders' Equity

Equity Plans

The Company has used long-term incentive plans for the purpose of granting equity awards to employees of the Company, including officers, and nonemployees, including consultants and nonemployee members of the Company's board of directors (collectively, the “Participants”). The Participants may receive awards as determined by a committee of independent members of the Company's board of directors or, to the extent authorized by such committee with respect to certain Participants, a duly authorized employee (collectively, the “Committee”). The incentive plan currently used by the Company is the 2018 Equity Incentive Compensation Plan (the “2018 Plan”), as adopted by the stockholders of the Company in June 2018, and subsequently increased by the stockholders of the Company in June 2021 with 6,000,000 shares authorized for issuance thereunder and in June of 2020 with 2,500,000 shares authorized for issuance thereunder, plus any shares awarded under the 2015 Equity Compensation Plan (the “2015 Plan”) or the Amended and Restated 2009 Equity Compensation Plan (the “2009 Plan”) that are not issued due to their subsequent forfeiture, cancellation, or other settlement thereof. Concurrent with the adoption of the 2018 Plan, no future awards will occur under the 2015 Plan or the 2009 Plan. The awards that may be made under the 2018 Plan include: (a) incentive stock options and nonqualified stock options, (b) shares of restricted stock, (c) restricted stock units, and (d) other kinds of equity-based compensation awards. All stock options under the 2015 Plan and 2009 Plan were granted and the 2018 Plan are granted at the fair market value of the common stock at the grant date. Stock options vest either on the date of grant, ratably over a period determined at time of grant, or upon the accomplishment of specified business milestones, and generally expire 2, 3, or 10 years from the grant date depending on the status of the recipient as a nonemployee, employee or director of the Company. As of December 31, 2021, there were 5,585,661 shares available for future grants under the 2018 Plan. No additional awards may be made under the 2015 Plan or the 2009 Plan.

The Company adopted an employee stock purchase plan effective January 1, 2013 and authorized 50,000 shares under the plan (the “2012 ESPP”). The plan has two six-month offering periods per year under which eligible employees may contribute up to 15% of their compensation toward the purchase of the Company's common stock per offering period (with a $25,000 cap per calendar year). The employee's purchase price is equal to (i) 85% of the closing price of a share of the Company's common stock on the enrollment date of such offering period or (ii) 85% of the closing price of a share of the Company's common stock on the Exercise Date of such Offering Period, whichever is lower. In May 2017, the Company's stockholders approved an amendment and restatement to the 2012 ESPP (the “2017 ESPP”) in order to effect an increase of authorized shares from 50,000 to 100,000. In June 2018, the Company's stockholders approved an amendment to the 2017 ESPP (the “Amended 2017 ESPP”) in order to effect an increase of authorized shares from 100,000 to 500,000. During the year ended December 31, 2021, 47,132 shares were issued under the Amended 2017 ESPP. At December 31, 2021, the Company had 300,577 shares of the Company's common stock available for future grant in connection with this plan.

Equity Issuances

Purchase Agreement

Pursuant to the Purchase Agreement, upon commencement Lincoln Park purchased 250,000 shares of common stock, at a price of $4.00 per share for a total gross purchase price of $1,000,000 (the “Initial Purchase”) upon commencement. Thereafter, as often as every business day from and after one business day following the date of the Initial Purchase and over the 36-month term of the Purchase Agreement, the Company has the right, from time to time, at its sole discretion and subject to certain conditions, to direct Lincoln Park to purchase up to 100,000 shares of common stock, with such amount increasing as the closing sale price of the common stock increases; provided Lincoln Park’s obligation under any single such purchase will not exceed $2,500,000, unless the Company and Lincoln Park mutually agree to increase the maximum amount of such single purchase (each, a “Regular Purchase”). If the Company directs Lincoln Park to purchase the maximum number of shares of common stock it then may sell in a Regular Purchase, then in addition to such Regular Purchase, and subject to certain conditions and limitations in the Purchase Agreement, the Company may direct Lincoln Park in an “accelerated purchase” to purchase an additional amount of common stock that may not exceed the lesser of (i) 300% the number of shares purchased pursuant to the corresponding Regular Purchase or (ii) 30% of the total number of shares of the Company’s common stock traded during a specified period on the applicable purchase date as set forth in the Purchase Agreement (each, an “Accelerated Purchase”). Under certain circumstances and in accordance with the Purchase Agreement, the Company may direct Lincoln Park to purchase shares in multiple accelerated purchases on the same trading day.

As of December 31, 2021, the Company had not made any sales of common stock to Lincoln Park under the Purchase Agreement other than the Initial Purchase. In addition, the Company may not direct Lincoln Park to make Accelerated Purchases under the Purchase Agreement if the stock is below the specified floor price of $1.00.

Common Stock Sales Agreement

In February 2018, the Company entered into a common stock sales agreement with H.C. Wainwright & Co., LLC (“HCW”) as sales agent, which was subsequently amended in August 2018 (the “Sales Agreement”), in connection with an “at the market offering” under which the Company from time to time may offer and sell shares of its common stock, having an aggregate offering price of not more than $25.0 million.

The Company provided HCW with customary indemnification rights, and HCW was entitled to a commission at a fixed commission rate equal to 3.0% of the gross proceeds per share sold.

On February 12, 2021, the Company suspended the use of the at-the-market transactions facility and terminated the continuous offering pursuant to the Sales Agreement.

As of the termination of the Sales Agreement on February 12, 2021, the Company had sold an aggregate 3,784,912 shares of its common stock pursuant to the Sales Agreement for net proceeds of $9.5 million since inception. For the year ended December 31, 2021, the Company had not issued any shares under the Sales Agreement.

At The Market Offering Agreement

On June 4, 2021, the Company entered into an At The Market Offering Agreement (the “ATM Agreement”) with HCW, as sales agent, in connection with an “at the market offering” under which the Company from time to time may offer and sell shares of its common stock, having an aggregate offering price of up to $50.0 million. During the twelve months ended December 31, 2021, the Company had not issued any shares under the ATM Agreement. Having received a listing deficiency notice from Nasdaq on February 18, 2022 after the Company’s shares traded below $1.00 for 30 consecutive trading days, the Company will not be permitted to sell additional shares under the ATM Agreement until it re-establishes timely compliance. Compliance may be reestablished by various mechanisms, including stock price appreciation at or above $1.00 for a requisite period of time and reverse stock split.

Registered Direct Offerings

In February 2021, the Company entered into a Securities Purchase Agreement (the “Institutional Purchase Agreement”) with certain institutional investors (the “Institutional Purchasers”). Pursuant to the terms of the Institutional Purchase Agreement, the Company sold to the Institutional Purchasers in a registered direct offering an aggregate of 24,906,134 shares of its common stock and warrants to purchase an aggregate of 12,453,067 shares of its common stock at a combined purchase price equal to $2.45 per share and associated warrant. Each warrant features an exercise price equal to $2.90 per share, is exercisable immediately upon issuance and will expire five years from the issuance date. Additionally, in a concurrent non-brokered registered direct offering, the Company entered into a Securities Purchase Agreement (the “Additional Purchase Agreement”) with certain accredited investors (the “Additional Purchasers”). Pursuant to the terms of the Additional Purchase Agreement, the Company sold to the Additional Purchasers an aggregate of 1,632,652 shares of its common stock and warrants to purchase an aggregate of 816,326 shares of its common stock at a combined purchase price equal to $2.45 per share and associated warrant. Each warrant features an exercise price equal to $2.90 per share, is exercisable immediately upon issuance and will expire five years from the issuance date. In connection with the registered direct offerings, the Company received gross proceeds of approximately $65.0 million.

Private Placement

In January 2021, the Company entered into a securities purchase agreement (the “January Private Placement”) with certain investors (the “January Purchasers”). Pursuant to the terms of the January Private Placement, the Company agreed to sell to the January Purchasers an aggregate of 12,500,000 shares of its common stock at a purchase price equal to $2.00 per share, along with warrants to purchase an aggregate of 6,250,000 shares of its common stock. In connection with the January Private Placement, the Company received gross proceeds of $25.0 million. Each warrant is exercisable for one share of common stock and features an exercise price equal to $2.90 per share. The warrants are exercisable immediately upon issuance and will expire five and one-half years from the issuance date.

Warrant Exercises

In January 2021, the Company issued 801,148 shares of common stock for net proceeds of $1.8 million in connection with warrant exercises associated with the April 23, 2020 securities purchase agreement and the May 25, 2020 securities purchase agreement.

Stock Options and Warrants

The following table summarizes the activity for stock options and warrants for the year ended December 31, 2021:

	Stock Options				Warrants
	Shares	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)	Shares	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)
Outstanding at December 31, 2020	963,700	$14.64	5.86	$—	2,638,355	$2.18	4.98	$—

Changes during the Year:
Granted	1,314,790	$1.32			19,519,393	$2.90
Exercised	(7,250)	$3.28		(3)	(801,148)	$2.19
Forfeited	(29,842)	$2.18			—	$—
Expired	(109,549)	$34.12			—	$—
Outstanding at December 31, 2021	2,131,849	$5.64	7.97	$—	21,356,600	$2.84	4.37	$—
Vested at December 31, 2021 or expected to vest in the future	2,120,643	$5.66	7.96	$—	21,356,600	$2.84	4.37	$—
Exercisable at December 31, 2021	1,122,783	$9.26	6.70	$—	21,356,600	$2.84	4.37	$—

Restricted Stock

During the years ended December 31, 2021 and 2020, the Company issued restricted stock for services as follows ($ in thousands, except share data):

	2021	2020
Number of Restricted Stock Issued	612,950	156,184
Value of Restricted Stock Issued	$877.7	$512.3

The weighted average estimated fair value of restricted stock issued for services in the years ended December 31, 2021 and 2020 was $1.43 and $3.28 per share, respectively. The fair value of the restricted stock was determined using the Company’s closing stock price on the date of issuance. The vesting terms of restricted stock issuances are generally between one to four years.

Restricted Stock Units

During the years ended December 31, 2021 and 2020, the Company issued restricted stock units for services as follows ($ in thousands, except share data):

	2021	2020
Number of Restricted Stock Units Issued	458,245	325,853
Value of Restricted Stock Units Issued	$728.6	$863.0

The weighted average estimated fair value of restricted stock units issued for services in the years ended December 31, 2021 and 2020 was $1.59 and $2.65 per share, respectively. The fair value of the restricted stock units was determined using the Company’s closing stock price on the date of issuance. The vesting terms of restricted stock unit issuances are generally one year, or upon the achievement of performance-based milestones.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Share-Based Compensation (FY)

3 Months Ended

12 Months Ended

Mar. 31, 2022

Dec. 31, 2021

Share-based Payment Arrangement [Abstract]

Share-Based Compensation

Note 9 – Share-Based Compensation

Share-Based Compensation

We utilize share-based compensation in the form of stock options, restricted stock, and restricted stock units. The following table summarizes the components of share-based compensation expense for the three months ended March 31, 2022 and 2021 (in thousands):

	Three Months Ended March 31,
	2022	2021
Research and development	$218	$96
General and administrative	542	501
Total share-based compensation expense	$760	$597

Total compensation cost related to non-vested awards not yet recognized and the weighted-average periods over which the awards were expected to be recognized at March 31, 2022 were as follows (in thousands):

	Stock Options	Restricted Stock Units	Restricted Stock
Unrecognized compensation cost	$814	$444	$1,004
Expected weighted-average period in years of compensation cost to be recognized	1.77	0.96	2.25

Total fair value of shares vested and the weighted average estimated fair values of shares granted for the three months ended March 31, 2022 and 2021 were as follows (in thousands):

Valuation Assumptions

The fair value of stock options and warrants at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon historical volatility of the Company’s stock. The expected term for the options is based upon observation of actual time elapsed between date of grant and exercise of options for all employees. The expected term for the warrants is based upon the contractual term of the warrants.

Note 10 – Share-Based Compensation

Share-based Compensation

The Company utilizes share-based compensation in the form of stock options, restricted stock, and restricted stock units. The following table summarizes the components of share-based compensation expense for the years ended December 31, 2021 and 2020 ($ in thousands):

	Year Ended December 31,
	2021	2020
Research and development	$760	$179
General and administrative	1,245	1,086
Total share-based compensation expense	$2,005	$1,265

Total compensation cost related to unvested awards not yet recognized and the weighted-average periods over which the awards are expected to be recognized at December 31, 2021 were as follows ($ in thousands):

	Stock Options	Restricted Stock Units	Restricted Stock
Unrecognized compensation cost	$757	$149	$546
Expected weighted-average period in years of compensation cost to be recognized	1.64	1.57	1.70

Total fair value of shares vested and the weighted average estimated fair values of shares granted for the years ended December 31, 2021 and 2020 were as follows ($ in thousands):

Valuation Assumptions

The fair value of stock options at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon historical volatility of the Company’s stock. The expected term for the options is based upon observation of actual time elapsed between date of grant and exercise of options for all employees.

The range of assumptions made in calculating the fair values of stock options was as follow:

	Stock Options
	Year Ended December 31,
	2021	2020
Expected term - minimum (in years)	6	6
Expected term - maximum (in years)	6	6
Expected volatility - minimum	79%	75%
Expected volatility - maximum	84%	79%
Weighted Average volatility	81%	75%
Expected dividend yield	—	—
Risk-free interest rate - minimum	0.63%	0.40%
Risk-free interest rate - maximum	1.16%	1.71%

Research Funding (FY)	12 Months Ended
Research Funding (FY)	Dec. 31, 2021
Research and Development [Abstract]
Research Funding	Note 11 – Research Funding California Institute of Regenerative Medicine Grant Award In February 2017, the California Institute for Regenerative Medicine (“CIRM”) awarded the Company funds of up to $12.2 million to support The Sanford Project: T-Rex Study, a prospective, randomized, placebo-controlled, double-blind Phase 2 clinical trial to evaluate the safety and efficacy of CLBS03 as a treatment for recent-onset type 1 diabetes. The funding is based upon the achievement of certain milestones related to the proportion of subjects enrolled in California, as well as manufacturing and development costs incurred in California. Based on the actual number of subjects enrolled in California, the total amount of funding was revised to $8.6 million, of which $8.2 million has been received through the grant project period completion. The Company received $5.7 million in initial funding in May 2017, a $1.9 million milestone payment in December 2017, a $0.3 million progress payment in March 2018, and a $0.2 million progress payment in May 2019, of which the total was amortized over the estimated award period through July 2020 as a reduction to the related research and development expenses, with the final true up payment of $46 thousand received in September 2020 and recorded as a reduction to the related research and development expenses. During the year ended December 31, 2021 and December 31, 2020 the Company amortized and recognized $0.0 million and $1.6 million in credits, respectively, to research and development related to CIRM funds received.

Income Taxes (FY)

3 Months Ended

12 Months Ended

Mar. 31, 2022

Dec. 31, 2021

Income Tax Disclosure [Abstract]

Income Taxes

Note 10 – Income Taxes

In assessing the realizability of deferred tax assets, including the net operating loss carryforwards (“NOLs”), the Company assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize its existing deferred tax assets. Based on its assessment, the Company has provided a full valuation allowance against its net deferred tax assets as their future utilization remains uncertain at this time.

As of December 31, 2021 and 2020, the Company had approximately $281 million and $264 million, respectively of federal NOLs available to offset future taxable income expiring from 2030 through 2036. The Company performed an analysis and determined that they had an ownership change of greater than 50% over a 3-year testing period on January 25, 2021. As a result, $169 million of the $281 million of federal NOLs will expire unutilized. The Company wrote off that portion of the deferred tax asset and reduced the corresponding valuation allowance resulting in $112 million of remaining federal NOL. The write off of the deferred tax asset and the corresponding reduction in valuation allowance has no impact to the balance sheet or income statement. Losses incurred before the ownership change on January 25, 2021 will be subject to an annual limitation of $173k under Internal Revenue Code Section 382, while losses incurred after January 25, 2021 will not be subject to limitations. The Company may be able to utilize additional NOLs of approximately $1.1 million per year for the first five years after this ownership change as a result of the application of the Net Unrealized Built-in Gain rules.

As of December 31, 2021 and 2020 the Company had State NOLs available in New Jersey of $97 million and $99 million, respectively, California of $70 million and $70 million, respectively, and New York City of $13 million and $13 million, respectively, to offset future taxable income expiring from 2031 through 2041. In accordance with Section 382 of the Internal Revenue code, the usage of the Company’s NOLs would be limited given the change in ownership. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period when those temporary differences become deductible.

The Company applies the FASB’s provisions for uncertain tax positions. The Company utilizes the two-step process to determine the amount of recognized tax benefit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recognizes interest and penalties associated with uncertain tax positions as a component of income tax expense.

As of March 31, 2022, management does not believe the Company has any material uncertain tax positions that would require it to measure and reflect the potential lack of sustainability of a position on audit in its financial statements. The Company will continue to evaluate its uncertain tax positions in future periods to determine if measurement and recognition in its financial statements is necessary. The Company does not believe there will be any material changes in its unrecognized tax positions over the next year.

For years prior to 2018, the federal statute of limitations is closed for assessing tax. The Company’s state tax returns remain open to examination for a period of three to four years from date of filing.

In December 2021, the Company received preliminary approval from the New Jersey Economic Development Authority (“NJEDA”) to participate in the Technology Business Tax Certificate Transfer Program (the “Program”). The Program permits qualified companies to sell a percentage of their New Jersey net operating losses (“NJ NOLs”) to unrelated profitable corporations. On February 22, 2022, the Company received final approval from NJEDA to sell $2.5 million of its NJ NOLs related tax benefits (“NJ NOL Tax Benefits”), which was subsequently sold to a qualifying and approved buyer pursuant to the Program for net proceeds of $2.3 million. The gross proceeds of $2.5 million have been recorded as a benefit from income taxes and the loss on sale of NJ NOLs of $0.1 million recorded in other income (expense) in the consolidated financial statements.

Note 12 – Income Taxes

The provision (benefit) for income taxes is based on loss from operations before provision for income taxes and noncontrolling interests as follows ($ in thousands):

	Years Ended December 31,
Pre-tax book income	2021	2020
United States	$(28,974)	$(19,013)
	$(28,974)	$(19,013)

The provision (benefit) from income taxes was as follows ($ in thousands):

	Years Ended December 31,
	2021	2020
Current
U.S. Federal	$—	$—
State and local	—	—
	$—	$—

Deferred
U.S. Federal	$—	$—
State and local	(1,508)	(10,872)
	$(1,508)	$(10,872)

Total
U.S. Federal	$—	$—
State and local	(1,508)	(10,872)
	$(1,508)	$(10,872)

The provision (benefit) for income taxes is determined by applying the U.S. Federal statutory rate of 21% to income before income taxes, and the components are set forth below ($ in thousands):

	Years Ended December 31,
	2021	2020
U.S. Federal benefit at statutory rate	$(6,085)	$(3,993)
Permanent non deductible expenses for U.S. taxes	320	5
Change in state deferred	622	5,122
Return to actual	2,277	—
Other true ups	1,407	387
Section 382 NOL Limitation	35,438	—
Sale of New Jersey State NOLs	(1,508)	(10,872)
Valuation allowance for deferred tax assets	(33,979)	(1,521)
Tax provision (benefit)	$(1,508)	$(10,872)

Deferred income taxes at December 31, 2021 and 2020 consist of the following ($ in thousands):

	December 31,
	2021	2020
Deferred Tax Assets:
Accumulated net operating losses (tax effected)	$36,281	$68,286
Right of use liability	201	176
Share-based compensation	3,086	5,025
Intangibles	97	131
Accumulated depreciation	26	19
Accrued payroll	176	167
Other	526	526
Deferred tax assets	40,393	74,330

Deferred Tax Liabilities:
Right of use asset	$(204)	$(161)
Deferred tax liabilities	(204)	(161)
	40,189	74,169
Valuation allowance	(40,189)	(74,169)
Net deferred tax asset	$—	$—

In assessing the realizability of deferred tax assets, including the net operating loss carryforwards (NOLs), the Company assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize its existing deferred tax assets. Based on its assessment, the Company has provided a full valuation allowance against its net deferred tax assets as their future utilization remains uncertain at this time.

As of December 31, 2021, and 2020, the Company had approximately $281 million and $264 million, respectively, of Federal NOLs available to offset future taxable income expiring from 2030 through 2036. The Company performed an analysis and determined that they had an ownership change of greater than 50% over a 3-year testing period on January 25, 2021. As a result, $169 million of the $281 million of Federal NOLs will expire unutilized. The Company wrote off that portion of the deferred tax asset and reduced the corresponding valuation allowance resulting in $112 million of remaining Federal NOL. The write off of the deferred tax asset and the corresponding reduction in valuation allowance has no impact to the balance sheet or income statement. Losses incurred before the ownership change on January 25, 2021 will be subject to an annual limitation of $173k under Internal Revenue Code Section 382, while losses incurred after January 25, 2021 will not be subject to limitations. The Company may be able to utilize additional NOLs of approximately $1.1 million per year for the first five years after this ownership change as a result of the application of the Net Unrealized Built-in Gain rules.

As of December 31, 2021 and 2020, the Company had State NOLs available in New Jersey of $97 million and $99 million, respectively, California of $70 million and $70 million, respectively, and New York City of $13 million and $13 million, respectively, to offset future taxable income expiring from 2031 through 2041. In accordance with Section 382 of the Internal Revenue code, the usage of the Company’s state NOLs would be limited given the change in ownership. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period when those temporary differences become deductible.

The Company applies the FASB’s provisions for uncertain tax positions. The Company utilizes the two-step process to determine the amount of recognized tax benefit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant taxing authority. The Company recognizes interest and penalties associated with certain tax positions as a component of income tax expense.

As of December 31, 2021, management does not believe the Company has any material uncertain tax positions that would require it to measure and reflect the potential lack of sustainability of a position on audit in its financial statements. The Company will continue to evaluate its uncertain tax positions in future periods to determine if measurement and recognition in its financial statements is necessary. The Company does not believe there will be any material changes in its unrecognized tax positions over the next year.

For years prior to 2018 the federal statute of limitations is closed for assessing tax. The Company’s state tax returns remain open to examination for a period of three to four years from date of filing.

In February 2021, the Company received preliminary approval from the New Jersey Economic Development Authority (“NJEDA”) to participate in the Technology Business Tax Certificate Transfer Program (the “Program”). The Program permits qualified companies to sell a percentage of their New Jersey net operating losses (“NJ NOLs”) to unrelated profitable corporations. On April 12, 2021, the Company received final approval from NJEDA to sell a portion of our NJ NOLs, which were subsequently sold to a qualifying and approved buyer pursuant to the Program for net proceeds of $1.4 million. The $1.5 million of our NJ NOL related tax benefits (“NJ NOL Tax Benefits”) have been recorded as a benefit from income taxes and the loss on sale of $0.1 million recorded in other income (expense) in the consolidated financial statements.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Contingencies (FY)	3 Months Ended	12 Months Ended
Contingencies (FY)	Mar. 31, 2022	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Note 11 – Contingencies Contingencies From time to time, the Company is subject to legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims cannot be predicted with certainty, the Company does not believe that the outcome of any pending claims will have a material adverse effect on the Company's financial condition or operating results.	Note 13 – Contingencies From time to time, the Company is subject to legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims cannot be predicted with certainty, the Company does not believe that the outcome of any pending claims will have a material adverse effect on the Company's financial condition or operating results.

The Business (Q1)

3 Months Ended

12 Months Ended

Mar. 31, 2022

Dec. 31, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

The Business

Note 1 – The Business

Overview

•	XOWNA^® (CLBS16), the subject of both a completed positive Phase 2a study (ESCaPE-CMD) and an ongoing follow on Phase 2b study (FREEDOM Trial) in the United States for the treatment of coronary microvascular dysfunction (“CMD”);

•

•	CLBS201, the subject of a study designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for patients with chronic kidney disease related to type 2 diabetes (diabetic kidney disease or “DKD”).

•

Ischemic Repair (CD34 Cell Technology)

XOWNA^® for Treatment of Coronary Microvascular Dysfunction

HONEDRA^® for Treatment of Critical Limb Ischemia

CLBS201 for Treatment of Diabetic Kidney Disease

Additional Out-licensing Opportunities and Pipeline Diversification

Coronavirus Considerations

Basis of Presentation

Use of Estimates

Principles of Consolidation

Note 1 – The Business

OVERVIEW

•	XOWNA^® (CLBS16), the subject of both a completed positive Phase 2a study (ESCaPE-CMD) and an ongoing follow-on Phase 2b study (FREEDOM Trial) in the United States for the treatment of coronary microvascular dysfunction (“CMD”);

•

•	CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for patients with chronic kidney disease related to type 2 diabetes (diabetic kidney disease or “DKD”).

Ischemic Repair (CD34 Cell Technology)

XOWNA^® for Treatment of Coronary Microvascular Dysfunction

HONEDRA^® for Treatment of Critical Limb Ischemia

The Company's randomized, open-label, registration-eligible study of HONEDRA^® in Japan for the treatment of CLI and Buerger's disease has, to date, demonstrated positive trends in both safety and efficacy. The HONEDRA^® study's enrollment, however, has been significantly curtailed by the COVID-19 pandemic's impact in Japan, including the States of Emergency in Japan that have persisted for much of the past 18 months. Due to the significant and continued operational and financial burden incurred as a result of these COVID-19 delays, coupled with the unpredictability of the timing of site enrollment re-initiation, Caladrius suspended further enrollment and is focusing its efforts on consummating a partnership for the product in Japan. Such a partnership may become the basis for the completion of development and registration of HONEDRA^® in Japan and may include the completion of enrollment of the four remaining no-option CLI subjects stipulated in the original protocol, if necessary, and/or exploration of the possibility of submitting the existing data to Japan's Pharmaceuticals and Medical Devices Agency (“PMDA”) under Japan's regenerative medicine regulations, which allow for conditional approval of innovative regenerative medicine products. Despite receipt from FDA in March 2021 of orphan designation in the U.S. for CLBS12 as a potential treatment for Buerger's disease, based on a response from the FDA in October 2021 regarding a development plan for U.S. registration the Company decided not to pursue United States development in Buerger's disease at this time.

CLBS201 for Treatment of Diabetic Kidney Disease

Progressive kidney failure is associated with attrition of the microcirculation of the kidney. Pre-clinical studies in kidney disease and injury models have demonstrated that protection or replenishment of the microcirculation results in improved kidney function. Based on these observations, the Company has elected to move forward with a Phase 1, open-label, proof-of-concept trial evaluating CLBS201 dosed via intra-renal artery injections in subjects with DKD. This protocol, as approved by an Institutional Review Board (the “IRB”), is expected to include six subjects in total with the first two subjects sequentially dosed and followed for a two-week safety observation period. Clearance by the independent Data Safety Monitoring Board (“DSMB”) overseeing the study will then permit the treatment of the next four patients, with all patients being followed for safety and therapeutic effect. A read-out of data will occur after at the six-month follow-up visit for all patients. A key criterion for continued development of CLBS201 will be its ability to demonstrate a therapeutic effect that will make it competitive in the field of DKD treatment, i.e., kidney function regeneration, as indicated by increased glomerular filtration rate.

Additional Out-licensing Opportunities and Pipeline Diversification

In addition, the Company further desires to diversify its pipeline of development products candidates and is exploring a range of strategic transactions in furtherance of that goal. The Company has taken, and intends to continue to take, active steps to identify assets and/or companies for acquisition and/or partnership that would complement its current development programs and de-risk its overall development portfolio. Such assets potentially could target indications beyond cardiovascular disease as well as product categories outside of cell therapy. The range of possible transactions includes an acquisition, merger, business combination, in-license or other strategic transaction, any of which could result in the issuance of securities that could significantly dilute

Coronavirus Considerations

In December 2019, a novel strain of coronavirus (SARS-CoV-2), which causes COVID-19, was reported to have surfaced in China. In March 2020, the World Health Organization declared the outbreak of COVID-19 to be a pandemic, and the world's economies began to experience pronounced effects. Despite the FDA approval of multiple COVID-19 vaccines in late 2020, there remains uncertainty around the extent and duration of disruption and any future related financial impact cannot reasonably be estimated at this time. In response to the COVID-19 pandemic, the Company implemented a universal work from home policy as well as stringent social distancing and other hygiene policies for employees when they must be in the office. The Company's clinical study of HONEDRA^® in Japan has experienced significant delays in enrollment due to the States of Emergency in effect in Japan for most of 2020 and re-implemented from January 7, 2021 through March 21, 2021 covering Tokyo and other regions in response to an increased number of COVID-19 infections. Due to reported increases in COVID-19 cases and a low rate of vaccination in Japan, States of Emergency were renewed on April 25, 2021 through May 11, 2021 and then re-implemented in Tokyo from July 12, 2021 through September 30, 2021. With the Company's expectation that

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

Use of Estimates

Principles of Consolidation

Summary of Significant Accounting Policies (Q1)

3 Months Ended

12 Months Ended

Mar. 31, 2022

Dec. 31, 2021

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 2 – Summary of Significant Accounting Policies

Concentration of Risks

Share-Based Compensation

Note 2 – Summary of Significant Accounting Policies

Cash and Cash Equivalents

Cash and cash equivalents include short-term, highly liquid, investments with maturities of ninety days or less when purchased.

Concentration of Risks

Marketable Securities

Property and Equipment

Furniture and fixtures			10 years
Computer equipment			3 years
Software			3 years
Leasehold improvements			Life of lease

Long-lived Assets

Share-Based Compensation

The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. Consultant awards are remeasured each reporting period through vesting. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. Stock based compensation expense also includes an estimate, which is made at the time of the grant, of the number of awards that are expected to be forfeited. The fair value of the Company’s restricted stock and restricted stock units is based on the closing market price of the Company’s common stock on the date of grant.

Loss Per Share

Treasury Stock

Research and Development Costs

New Accounting Pronouncements

Available-for-Sale-Securities (Q1)

3 Months Ended

12 Months Ended

Mar. 31, 2022

Dec. 31, 2021

Debt Securities, Available-for-sale [Abstract]

Available-for-Sale-Securities

Note 3 – Available-for-Sale-Securities

The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):

	March 31, 2022				December 31, 2021
	Cost	Gross Unrealized Gains	Gross Unrealized Losses	Estimated Fair Value	Cost	Gross Unrealized Gains	Gross Unrealized Losses	Estimated Fair Value
Corporate debt securities	$62,770	$—	$(162)	$62,608	$53,135	$—	$(65)	$53,070
Money market funds	6,578	—	—	6,578	18,124	—	—	18,124
Municipal debt securities	17,267	—	(34)	17,233	20,263	—	(5)	20,258
Total	$86,615	$—	$(196)	$86,419	$91,522	$—	$(70)	$91,452

	March 31, 2022	December 31, 2021
Cash equivalents	$10,647	$21,129
Marketable securities	75,772	70,323
Total	$86,419	$91,452

The following table summarizes our portfolio of available-for-sale securities by contractual maturity (in thousands):

	March 31, 2022
	Amortized Cost	Estimated Fair Value
Less than one year	$86,615	$86,419
Greater than one year		—
Total	$86,615	$86,419

Note 3 – Available-for-Sale-Securities

The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or debt marketable securities in the Company's Consolidated Balance Sheets (in thousands):

	December 31, 2021				December 31, 2020
	Cost	Gross Unrealized Gains	Gross Unrealized Losses	Estimated Fair Value	Cost	Gross Unrealized Gains	Gross Unrealized Losses	Estimated Fair Value
Corporate debt securities	$53,135	$—	$(65)	$53,070	$8,406	$—	$(7)	$8,399
Money market funds	18,124	—	—	18,124	7,591	—	—	7,591
Municipal debt securities	20,263	—	(5)	20,258	14,753	—	(6)	14,747
Total	$91,522	$—	$(70)	$91,452	$30,750	$—	$(13)	$30,737

Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale debt securities on the Company's Consolidated Balance Sheets (in thousands):

	December 31, 2021	December 31, 2020
Cash and cash equivalents	$21,129	$12,676
Marketable securities	70,323	18,061
Total	$91,452	$30,737

The following table summarizes the Company's portfolio of available-for-sale securities by contractual maturity (in thousands):

	December 31, 2021		December 31, 2020
	Amortized Cost	Estimated Fair Value	Amortized Cost	Estimated Fair Value
Less than one year	$91,522	$91,452	$30,750	$30,737
Greater than one year	—	—	—	—
Total	$91,522	$91,452	$30,750	$30,737

Income (Loss) Per Share (Q1)

3 Months Ended

12 Months Ended

Mar. 31, 2022

Dec. 31, 2021

Earnings Per Share [Abstract]

Income (Loss) Per Share

Note 4 – Income (Loss) Per Share

	March 31,
	2022	2021
Stock Options	2,640	1,022
Warrants	21,357	21,357
Restricted Stock Units	1,460	798

Note 5 – Loss Per Share

	December 31,
	2021	2020
Stock Options	2,132	964
Warrants	21,357	2,638
Restricted Stock Units	604	340

Fair Value Measurements (Q1)

3 Months Ended

12 Months Ended

Mar. 31, 2022

Dec. 31, 2021

Fair Value Disclosures [Abstract]

Fair Value Measurements

Note 5 – Fair Value Measurements

Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.

Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.

	March 31, 2022				December 31, 2021
	Level 1	Level 2	Level 3	Total	Level 1	Level 2	Level 3	Total
Assets:
Marketable securities - available for sale	$—	$75,772	$—	$75,772	$—	$70,323	$—	$70,323
	$—	$75,772	$—	$75,772	$—	$70,323	$—	$70,323

Note 6 – Fair Value Measurements

Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.

Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.

The Company's financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2021 and December 31, 2020 were as follows (in thousands):

	December 31, 2021				December 31, 2020
	Level 1	Level 2	Level 3	Total	Level 1	Level 2	Level 3	Total
Assets:
Marketable securities - available for sale	$—	$70,323	$—	$70,323	$—	$18,061	$—	$18,061
	$—	$70,323	$—	$70,323	$—	$18,061	$—	$18,061

- Definition

+ References + Details

Accrued Liabilities (Q1)

3 Months Ended

12 Months Ended

Mar. 31, 2022

Dec. 31, 2021

Accrued Liabilities [Abstract]

Accrued Liabilities

Note 6 – Accrued Liabilities

Accrued liabilities as of March 31, 2022 and December 31, 2021 were as follows (in thousands):

	March 31, 2022	December 31, 2021
Salaries, employee benefits and related taxes	$1,005	$2,034
Operating lease liabilities — current	205	229
Other	894	326
Total	$2,104	$2,589

Note 7 – Accrued Liabilities

Accrued liabilities were as follow (in thousands):

	December 31,
	2021	2020
Salaries, employee benefits and related taxes	$2,034	$1,716
Operating lease liabilities - current	229	370
Other	326	400
	$2,589	$2,486

Operating Leases (Q1)

3 Months Ended

12 Months Ended

Mar. 31, 2022

Dec. 31, 2021

Leases [Abstract]

Operating Leases

Note 7 – Operating Leases

Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet were as follows (in thousands):

	March 31, 2022	December 31, 2021
Right-of Use Assets:
Other assets	$667	$724
Total Right-of-Use Asset	$667	$724

Operating Lease Liabilities:
Accrued liabilities	$205	$229
Other long-term liabilities	421	485
Total Operating Lease Liabilities	$626	$714

Years ended			Operating Leases
2022			181
2023			217
2024			190
2025			143
Total lease payments			731
Less: Amounts representing interest			(105)
Present value of lease liabilities			$626

Note 8 – Operating Leases

Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet as follows (in thousands):

	December 31, 2021	December 31, 2020
Right-of Use Assets:
Other assets	$724	$574
Total Right-of-Use Asset	$724	$574

Operating Lease Liabilities:
Accrued liabilities	$229	$370
Other long-term liabilities	485	254
Total Operating Lease Liabilities	$714	$624

Years ended			Operating Leases
2022			$286
2023			217
2024			190
2025			143
Total lease payments			836
Less: Amounts representing interest			(122)
Present value of lease liabilities			$714

Stockholders' Equity (Q1)

3 Months Ended

12 Months Ended

Mar. 31, 2022

Dec. 31, 2021

Equity [Abstract]

Stockholders' Equity

Note 8 – Stockholders' Equity

Equity Issuances

Purchase Agreement

As of March 31, 2022, the Company had not made any sales of common stock to Lincoln Park under the Purchase Agreement other than the Initial Purchase. The agreement expired on April 1, 2022.

At The Market Offering Agreement

Stock Options and Warrants

The following table summarizes the activity for stock options and warrants for the three months ended March 31, 2022:

	Stock Options				Warrants
	Shares	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)	Shares	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)
Outstanding at December 31, 2021	2,131,849	$5.64	7.97	$—	21,356,600	$2.84	4.37	$—

Changes during the period:
Granted	540,600	0.91			—	—
Exercised	—	—			—	—
Forfeited	(9,565)	1.90			—	—
Expired	(23,275)	26.00			—	—
Outstanding at March 31, 2022	2,639,609	$4.51	7.83	$—	21,356,600	$2.84	4.13	$—
Vested at March 31, 2022 or expected to vest in the future	2,594,630	$4.57	7.80	$—	21,356,600	$2.84	4.13	$—
Vested at March 31, 2022	1,408,083	$7.36	6.41	$—	21,356,600	$2.84	4.13	$—

Restricted Stock

During the three months ended March 31, 2022 and 2021, the Company issued restricted stock for services as follows ($ in thousands):

	Three Months Ended March 31,
	2022	2021
Number of restricted stock issued	1,061,175	300,450
Value of restricted stock issued	$973	$478

The vesting terms of restricted stock issuances are generally between one to four years.

Restricted Stock Units

During the three months ended March 31, 2022 and 2021, the Company issued restricted stock units for services as follows ($ in thousands, except share data):

	Three Months Ended March 31,
	2022	2021
Number of restricted stock units issued	1,379,860	458,245
Value of restricted stock units issued	$1,265	$729

Note 9 – Stockholders' Equity

Equity Plans

Equity Issuances

Purchase Agreement

Common Stock Sales Agreement

The Company provided HCW with customary indemnification rights, and HCW was entitled to a commission at a fixed commission rate equal to 3.0% of the gross proceeds per share sold.

On February 12, 2021, the Company suspended the use of the at-the-market transactions facility and terminated the continuous offering pursuant to the Sales Agreement.

At The Market Offering Agreement

On June 4, 2021, the Company entered into an At The Market Offering Agreement (the “ATM Agreement”) with HCW, as sales agent, in connection with an “at the market offering” under which the Company from time to time may offer and sell shares of its common stock, having an aggregate offering price of up to $50.0 million. During the twelve months ended December 31, 2021, the Company had not issued any shares under the ATM Agreement. Having received a listing deficiency notice from Nasdaq on February 18, 2022 after the Company’s shares traded below $1.00 for 30 consecutive trading days, the Company will not be permitted to sell additional shares under the ATM Agreement until it re-establishes timely compliance. Compliance may be reestablished by various mechanisms, including stock price appreciation at or above $1.00 for a requisite period of time and reverse stock split.

Registered Direct Offerings

Private Placement

Warrant Exercises

Stock Options and Warrants

The following table summarizes the activity for stock options and warrants for the year ended December 31, 2021:

	Stock Options				Warrants
	Shares	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)	Shares	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)
Outstanding at December 31, 2020	963,700	$14.64	5.86	$—	2,638,355	$2.18	4.98	$—

Changes during the Year:
Granted	1,314,790	$1.32			19,519,393	$2.90
Exercised	(7,250)	$3.28		(3)	(801,148)	$2.19
Forfeited	(29,842)	$2.18			—	$—
Expired	(109,549)	$34.12			—	$—
Outstanding at December 31, 2021	2,131,849	$5.64	7.97	$—	21,356,600	$2.84	4.37	$—
Vested at December 31, 2021 or expected to vest in the future	2,120,643	$5.66	7.96	$—	21,356,600	$2.84	4.37	$—
Exercisable at December 31, 2021	1,122,783	$9.26	6.70	$—	21,356,600	$2.84	4.37	$—

Restricted Stock

During the years ended December 31, 2021 and 2020, the Company issued restricted stock for services as follows ($ in thousands, except share data):

	2021	2020
Number of Restricted Stock Issued	612,950	156,184
Value of Restricted Stock Issued	$877.7	$512.3

Restricted Stock Units

During the years ended December 31, 2021 and 2020, the Company issued restricted stock units for services as follows ($ in thousands, except share data):

	2021	2020
Number of Restricted Stock Units Issued	458,245	325,853
Value of Restricted Stock Units Issued	$728.6	$863.0

- Definition

+ References

+ Details

Share-Based Compensation (Q1)

3 Months Ended

12 Months Ended

Mar. 31, 2022

Dec. 31, 2021

Share-based Payment Arrangement [Abstract]

Share-Based Compensation

Note 9 – Share-Based Compensation

Share-Based Compensation

	Three Months Ended March 31,
	2022	2021
Research and development	$218	$96
General and administrative	542	501
Total share-based compensation expense	$760	$597

	Stock Options	Restricted Stock Units	Restricted Stock
Unrecognized compensation cost	$814	$444	$1,004
Expected weighted-average period in years of compensation cost to be recognized	1.77	0.96	2.25

Total fair value of shares vested and the weighted average estimated fair values of shares granted for the three months ended March 31, 2022 and 2021 were as follows (in thousands):

Valuation Assumptions

Note 10 – Share-Based Compensation

Share-based Compensation

	Year Ended December 31,
	2021	2020
Research and development	$760	$179
General and administrative	1,245	1,086
Total share-based compensation expense	$2,005	$1,265

	Stock Options	Restricted Stock Units	Restricted Stock
Unrecognized compensation cost	$757	$149	$546
Expected weighted-average period in years of compensation cost to be recognized	1.64	1.57	1.70

Total fair value of shares vested and the weighted average estimated fair values of shares granted for the years ended December 31, 2021 and 2020 were as follows ($ in thousands):

Valuation Assumptions

The range of assumptions made in calculating the fair values of stock options was as follow:

	Stock Options
	Year Ended December 31,
	2021	2020
Expected term - minimum (in years)	6	6
Expected term - maximum (in years)	6	6
Expected volatility - minimum	79%	75%
Expected volatility - maximum	84%	79%
Weighted Average volatility	81%	75%
Expected dividend yield	—	—
Risk-free interest rate - minimum	0.63%	0.40%
Risk-free interest rate - maximum	1.16%	1.71%

Income Taxes (Q1)

3 Months Ended

12 Months Ended

Mar. 31, 2022

Dec. 31, 2021

Income Tax Disclosure [Abstract]

Income Taxes

Note 10 – Income Taxes

Note 12 – Income Taxes

The provision (benefit) for income taxes is based on loss from operations before provision for income taxes and noncontrolling interests as follows ($ in thousands):

	Years Ended December 31,
Pre-tax book income	2021	2020
United States	$(28,974)	$(19,013)
	$(28,974)	$(19,013)

The provision (benefit) from income taxes was as follows ($ in thousands):

	Years Ended December 31,
	2021	2020
Current
U.S. Federal	$—	$—
State and local	—	—
	$—	$—

Deferred
U.S. Federal	$—	$—
State and local	(1,508)	(10,872)
	$(1,508)	$(10,872)

Total
U.S. Federal	$—	$—
State and local	(1,508)	(10,872)
	$(1,508)	$(10,872)

The provision (benefit) for income taxes is determined by applying the U.S. Federal statutory rate of 21% to income before income taxes, and the components are set forth below ($ in thousands):

	Years Ended December 31,
	2021	2020
U.S. Federal benefit at statutory rate	$(6,085)	$(3,993)
Permanent non deductible expenses for U.S. taxes	320	5
Change in state deferred	622	5,122
Return to actual	2,277	—
Other true ups	1,407	387
Section 382 NOL Limitation	35,438	—
Sale of New Jersey State NOLs	(1,508)	(10,872)
Valuation allowance for deferred tax assets	(33,979)	(1,521)
Tax provision (benefit)	$(1,508)	$(10,872)

Deferred income taxes at December 31, 2021 and 2020 consist of the following ($ in thousands):

	December 31,
	2021	2020
Deferred Tax Assets:
Accumulated net operating losses (tax effected)	$36,281	$68,286
Right of use liability	201	176
Share-based compensation	3,086	5,025
Intangibles	97	131
Accumulated depreciation	26	19
Accrued payroll	176	167
Other	526	526
Deferred tax assets	40,393	74,330

Deferred Tax Liabilities:
Right of use asset	$(204)	$(161)
Deferred tax liabilities	(204)	(161)
	40,189	74,169
Valuation allowance	(40,189)	(74,169)
Net deferred tax asset	$—	$—

The Company applies the FASB’s provisions for uncertain tax positions. The Company utilizes the two-step process to determine the amount of recognized tax benefit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant taxing authority. The Company recognizes interest and penalties associated with certain tax positions as a component of income tax expense.

- Definition

+ References

+ Details

Contingencies (Q1)	3 Months Ended	12 Months Ended
Contingencies (Q1)	Mar. 31, 2022	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Note 11 – Contingencies Contingencies From time to time, the Company is subject to legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims cannot be predicted with certainty, the Company does not believe that the outcome of any pending claims will have a material adverse effect on the Company's financial condition or operating results.	Note 13 – Contingencies From time to time, the Company is subject to legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims cannot be predicted with certainty, the Company does not believe that the outcome of any pending claims will have a material adverse effect on the Company's financial condition or operating results.

Subsequent Events (Q1)	3 Months Ended
Subsequent Events (Q1)	Mar. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	Note 12 – Subsequent Event Cend Merger Agreement On April 26, 2022, the Company and Cend Therapeutics, Inc., a Delaware corporation (“Cend”), entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, a wholly-owned subsidiary of Caladrius will merge with and into Cend, with Cend surviving as a wholly-owned subsidiary of the Company (the “Merger”), subject to the terms of the Merger Agreement and stockholder approval of the transaction. Under the exchange ratio formula, as of immediately after the Merger, the former Cend stockholders are expected to own approximately 50% of the outstanding shares of Caladrius Common Stock and the Company’s stockholders as of immediately prior to the Merger are expected to own approximately 50% of the outstanding shares of Caladrius Common Stock. The actual allocation will be subject to adjustment based on the Company’s net cash balance at the time of closing and the amount of any transaction expenses of Cend in excess of $250 thousand at the time of closing. Consummation of the Merger is subject to certain closing conditions, including, among other things, approval by the stockholders of the Company and Cend, and the Company’s satisfaction of a minimum net cash threshold at closing, expected to be approximately $64.9 million assuming a closing at the end of the third quarter of 2022, and as described further in the Merger Agreement. The Merger Agreement contains certain termination rights for both the Company and Cend, and further provides that, upon termination of the Merger Agreement under specified circumstances, the Company may be required to pay Cend a termination fee of $1.0 million, Cend may be required to pay the Company a termination fee of $4.0 million, or in some circumstances reimburse the other party’s expenses up to a maximum of $1.0 million. At the effective time of the Merger, the Company’s Board of Directors is expected to consist of nine members, four of whom will be designated by the Company, four of whom will be designated by Cend and one member who will be mutually agreed between the Company and Cend. Stock Purchase Agreement In order to provide Cend with capital for its development programs prior to the closing of the Merger, the Company and Cend entered into a Series D Preferred Stock Purchase Agreement (the “Purchase Agreement”), pursuant to which the Company agreed to purchase from Cend 1,135,628 shares of Series D Preferred Stock, $0.00001 par value per share (the “Series D Preferred Stock”), of Cend at a purchase price per share equal to $8.8057 per share (the “Series D Original Issue Price”), or approximately $10 million in the aggregate. The Series D Preferred Stock ranks senior to Cend’s common stock and the other series of preferred stock with respect to rights on the distribution of assets on any voluntary or involuntary liquidation, dissolution or winding up of Cend. The Series D Preferred Stock has a liquidation preference equal to the Series D Original Issue Price plus an amount equal to any accrued and unpaid dividends to the date of payment and will participate with Cend’s common stockholders and other preferred stockholders thereafter on an as-converted basis. The Series D Preferred Stock shall vote with the common stock on an as-converted basis on any matters presented to the stockholders of Cend. Each share of Series D Preferred Stock is convertible, at the option of the holder thereof, into such number of shares of Cend common stock as is determined by dividing the Original Issue Price by the conversion price in effect at the time of conversion, which conversion price shall be the Original Issue Price as appropriately adjusted for stock splits, stock dividends, combinations, and subdivisions of Cend common stock, and as adjusted pursuant to a weighted-average antidilution adjustment. The Series D Preferred Stock will automatically convert into shares of Cend common stock upon the closing of a firm-commitment underwritten initial public offering implying a pre-equity offering value of at least $250 million, resulting in at least $50 million of gross proceeds to Cend. Collaboration Agreement In connection with such Purchase Agreement, Cend entered into a Collaboration Agreement (the “Collaboration Agreement”), pursuant to which the Company agreed to collaborate with Cend on certain developmental and clinical activities prior to the closing of the Merger. Under the Collaboration Agreement, the Company and Cend will form a joint steering committee (the “Committee”) comprised of individuals from both entities. The Committee will meet regularly and be responsible for monitoring ongoing studies and making recommendations for development activity and trial planning. Cend has agreed to pay each member of the Committee from the Company an hourly consulting fee for such service.

Summary of Significant Accounting Policies (FY) (Policies)

3 Months Ended

12 Months Ended

Mar. 31, 2022

Dec. 31, 2021

Accounting Policies [Abstract]

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

Use of Estimates

Principles of Consolidation

Cash and Cash Equivalents

Cash and cash equivalents include short-term, highly liquid, investments with maturities of ninety days or less when purchased.

Concentration of Risks

Marketable Securities

Property and Equipment

Furniture and fixtures			10 years
Computer equipment			3 years
Software			3 years
Leasehold improvements			Life of lease

Long-lived Assets

Share-Based Compensation

The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. Consultant awards are remeasured each reporting period through vesting. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. Stock based compensation expense also includes an estimate, which is made at the time of the grant, of the number of awards that are expected to be forfeited. The fair value of the Company’s restricted stock and restricted stock units is based on the closing market price of the Company’s common stock on the date of grant.

Loss Per Share

Treasury Stock

Research and Development Costs

New Accounting Pronouncements

Summary of Significant Accounting Policies (Q1) (Policies)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company’s financial position as of March 31, 2022, and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December 31, 2021 and 2020 included in our 2021 Form 10-K. Operating results for the three months ended March 31, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022.	Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining stock-based awards values. Accordingly, actual results could differ from those estimates and assumptions.	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimate and assumptions in determining stock-based awards values. Accordingly, actual results could differ from those estimates and assumptions.
Principles of Consolidation	Principles of Consolidation The Consolidated Financial Statements include the accounts of Caladrius Biosciences, Inc. and its wholly owned and majority owned subsidiaries and affiliates. All intercompany activities have been eliminated in consolidation.	Principles of Consolidation The Consolidated Financial Statements include the accounts of Caladrius Biosciences, Inc. and its wholly owned and majority owned subsidiaries and affiliates. All intercompany activities have been eliminated in consolidation.
Concentration of Risks	Concentration of Risks The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States. Therefore, the Company is not exposed to any significant concentrations of credit risk from these financial instruments. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.	Concentration of Risks The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States. Therefore, the Company is not exposed to any significant concentrations of credit risk from these financial instruments. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.
Share-Based Compensation	Share-Based Compensation The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. Consultant awards are remeasured each reporting period through vesting. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. The fair value of the Company’s restricted stock and restricted stock units is based on the closing market price of the Company’s common stock on the date of grant.	Share-Based Compensation The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. Consultant awards are remeasured each reporting period through vesting. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. Stock based compensation expense also includes an estimate, which is made at the time of the grant, of the number of awards that are expected to be forfeited. The fair value of the Company’s restricted stock and restricted stock units is based on the closing market price of the Company’s common stock on the date of grant.

Summary of Significant Accounting Policies (FY) (Tables)

12 Months Ended

Dec. 31, 2021

Accounting Policies [Abstract]

Schedule of Property and Equipment

The estimated useful lives of property and equipment are as follows:

Furniture and fixtures			10 years
Computer equipment			3 years
Software			3 years
Leasehold improvements			Life of lease

Property and equipment consisted of the following (in thousands):

	December 31,
	2021	2020
Furniture and fixtures	$26	$26
Computer equipment	314	254
Leasehold improvements	90	90
Property and equipment, gross	430	370
Accumulated depreciation	(368)	(313)
Property and equipment, net	$62	$57

Available-for-Sale-Securities (FY) (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2022

Dec. 31, 2021

Investments, Debt and Equity Securities [Abstract]

Schedule of Available-for-Sale Securities Reconciliation

The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):

	March 31, 2022				December 31, 2021
	Cost	Gross Unrealized Gains	Gross Unrealized Losses	Estimated Fair Value	Cost	Gross Unrealized Gains	Gross Unrealized Losses	Estimated Fair Value
Corporate debt securities	$62,770	$—	$(162)	$62,608	$53,135	$—	$(65)	$53,070
Money market funds	6,578	—	—	6,578	18,124	—	—	18,124
Municipal debt securities	17,267	—	(34)	17,233	20,263	—	(5)	20,258
Total	$86,615	$—	$(196)	$86,419	$91,522	$—	$(70)	$91,452

The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or debt marketable securities in the Company's Consolidated Balance Sheets (in thousands):

	December 31, 2021				December 31, 2020
	Cost	Gross Unrealized Gains	Gross Unrealized Losses	Estimated Fair Value	Cost	Gross Unrealized Gains	Gross Unrealized Losses	Estimated Fair Value
Corporate debt securities	$53,135	$—	$(65)	$53,070	$8,406	$—	$(7)	$8,399
Money market funds	18,124	—	—	18,124	7,591	—	—	7,591
Municipal debt securities	20,263	—	(5)	20,258	14,753	—	(6)	14,747
Total	$91,522	$—	$(70)	$91,452	$30,750	$—	$(13)	$30,737

Schedule of Marketable Securities

	March 31, 2022	December 31, 2021
Cash equivalents	$10,647	$21,129
Marketable securities	75,772	70,323
Total	$86,419	$91,452

Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale debt securities on the Company's Consolidated Balance Sheets (in thousands):

	December 31, 2021	December 31, 2020
Cash and cash equivalents	$21,129	$12,676
Marketable securities	70,323	18,061
Total	$91,452	$30,737

Schedule of Available-for-Sale Securities by Contractual Maturity

The following table summarizes our portfolio of available-for-sale securities by contractual maturity (in thousands):

	March 31, 2022
	Amortized Cost	Estimated Fair Value
Less than one year	$86,615	$86,419
Greater than one year		—
Total	$86,615	$86,419

The following table summarizes the Company's portfolio of available-for-sale securities by contractual maturity (in thousands):

	December 31, 2021		December 31, 2020
	Amortized Cost	Estimated Fair Value	Amortized Cost	Estimated Fair Value
Less than one year	$91,522	$91,452	$30,750	$30,737
Greater than one year	—	—	—	—
Total	$91,522	$91,452	$30,750	$30,737

Property and Equipment (FY) (Tables)

12 Months Ended

Dec. 31, 2021

Property, Plant and Equipment [Abstract]

Schedule of Property and Equipment

The estimated useful lives of property and equipment are as follows:

Furniture and fixtures			10 years
Computer equipment			3 years
Software			3 years
Leasehold improvements			Life of lease

Property and equipment consisted of the following (in thousands):

	December 31,
	2021	2020
Furniture and fixtures	$26	$26
Computer equipment	314	254
Leasehold improvements	90	90
Property and equipment, gross	430	370
Accumulated depreciation	(368)	(313)
Property and equipment, net	$62	$57

Loss Per Share (FY) (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2022

Dec. 31, 2021

Earnings Per Share [Abstract]

Schedule of Antidilutive Securities Excluded from Computation of Loss Per Share

At March 31, 2022 and 2021, the Company excluded the following potentially dilutive securities (in thousands):

	March 31,
	2022	2021
Stock Options	2,640	1,022
Warrants	21,357	21,357
Restricted Stock Units	1,460	798

At December 31, 2021 and 2020, the Company excluded the following potentially dilutive securities (in thousands):

	December 31,
	2021	2020
Stock Options	2,132	964
Warrants	21,357	2,638
Restricted Stock Units	604	340

Fair Value Measurements (FY) (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2022

Dec. 31, 2021

Fair Value Disclosures [Abstract]

Schedule of Fair Value of Assets Measured on Recurring Basis

	March 31, 2022				December 31, 2021
	Level 1	Level 2	Level 3	Total	Level 1	Level 2	Level 3	Total
Assets:
Marketable securities - available for sale	$—	$75,772	$—	$75,772	$—	$70,323	$—	$70,323
	$—	$75,772	$—	$75,772	$—	$70,323	$—	$70,323

The Company's financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2021 and December 31, 2020 were as follows (in thousands):

	December 31, 2021				December 31, 2020
	Level 1	Level 2	Level 3	Total	Level 1	Level 2	Level 3	Total
Assets:
Marketable securities - available for sale	$—	$70,323	$—	$70,323	$—	$18,061	$—	$18,061
	$—	$70,323	$—	$70,323	$—	$18,061	$—	$18,061

Accrued Liabilities (FY) (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2022

Dec. 31, 2021

Accrued Liabilities [Abstract]

Schedule of Accrued Liabilities

Accrued liabilities as of March 31, 2022 and December 31, 2021 were as follows (in thousands):

	March 31, 2022	December 31, 2021
Salaries, employee benefits and related taxes	$1,005	$2,034
Operating lease liabilities — current	205	229
Other	894	326
Total	$2,104	$2,589

Accrued liabilities were as follow (in thousands):

	December 31,
	2021	2020
Salaries, employee benefits and related taxes	$2,034	$1,716
Operating lease liabilities - current	229	370
Other	326	400
	$2,589	$2,486

Operating Leases (FY) (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2022

Dec. 31, 2021

Leases [Abstract]

Schedule of Operating Lease Liabilities and Right-of-Use Assets on Balance Sheet

Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet were as follows (in thousands):

	March 31, 2022	December 31, 2021
Right-of Use Assets:
Other assets	$667	$724
Total Right-of-Use Asset	$667	$724

Operating Lease Liabilities:
Accrued liabilities	$205	$229
Other long-term liabilities	421	485
Total Operating Lease Liabilities	$626	$714

Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet as follows (in thousands):

	December 31, 2021	December 31, 2020
Right-of Use Assets:
Other assets	$724	$574
Total Right-of-Use Asset	$724	$574

Operating Lease Liabilities:
Accrued liabilities	$229	$370
Other long-term liabilities	485	254
Total Operating Lease Liabilities	$714	$624

Schedule of Future Minimum Lease Payments Under Lease Agreements

Future minimum lease payments under the lease agreements as of March 31, 2022 were as follows (in thousands):

Years ended			Operating Leases
2022			181
2023			217
2024			190
2025			143
Total lease payments			731
Less: Amounts representing interest			(105)
Present value of lease liabilities			$626

Future minimum lease payments under the lease agreements as of December 31, 2021 were as follows (in thousands):

Years ended			Operating Leases
2022			$286
2023			217
2024			190
2025			143
Total lease payments			836
Less: Amounts representing interest			(122)
Present value of lease liabilities			$714

Stockholders' Equity (FY) (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2022

Dec. 31, 2021

Equity [Abstract]

Schedule of Stock Options and Warrants Activity

The following table summarizes the activity for stock options and warrants for the three months ended March 31, 2022:

	Stock Options				Warrants
	Shares	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)	Shares	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)
Outstanding at December 31, 2021	2,131,849	$5.64	7.97	$—	21,356,600	$2.84	4.37	$—

Changes during the period:
Granted	540,600	0.91			—	—
Exercised	—	—			—	—
Forfeited	(9,565)	1.90			—	—
Expired	(23,275)	26.00			—	—
Outstanding at March 31, 2022	2,639,609	$4.51	7.83	$—	21,356,600	$2.84	4.13	$—
Vested at March 31, 2022 or expected to vest in the future	2,594,630	$4.57	7.80	$—	21,356,600	$2.84	4.13	$—
Vested at March 31, 2022	1,408,083	$7.36	6.41	$—	21,356,600	$2.84	4.13	$—

The following table summarizes the activity for stock options and warrants for the year ended December 31, 2021:

	Stock Options				Warrants
	Shares	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)	Shares	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)
Outstanding at December 31, 2020	963,700	$14.64	5.86	$—	2,638,355	$2.18	4.98	$—

Changes during the Year:
Granted	1,314,790	$1.32			19,519,393	$2.90
Exercised	(7,250)	$3.28		(3)	(801,148)	$2.19
Forfeited	(29,842)	$2.18			—	$—
Expired	(109,549)	$34.12			—	$—
Outstanding at December 31, 2021	2,131,849	$5.64	7.97	$—	21,356,600	$2.84	4.37	$—
Vested at December 31, 2021 or expected to vest in the future	2,120,643	$5.66	7.96	$—	21,356,600	$2.84	4.37	$—
Exercisable at December 31, 2021	1,122,783	$9.26	6.70	$—	21,356,600	$2.84	4.37	$—

Schedule of Restricted Stock

During the three months ended March 31, 2022 and 2021, the Company issued restricted stock for services as follows ($ in thousands):

	Three Months Ended March 31,
	2022	2021
Number of restricted stock issued	1,061,175	300,450
Value of restricted stock issued	$973	$478

During the years ended December 31, 2021 and 2020, the Company issued restricted stock for services as follows ($ in thousands, except share data):

	2021	2020
Number of Restricted Stock Issued	612,950	156,184
Value of Restricted Stock Issued	$877.7	$512.3

Schedule of Restricted Stock Units

During the years ended December 31, 2021 and 2020, the Company issued restricted stock units for services as follows ($ in thousands, except share data):

	2021	2020
Number of Restricted Stock Units Issued	458,245	325,853
Value of Restricted Stock Units Issued	$728.6	$863.0

Share-Based Compensation (FY) (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2022

Dec. 31, 2021

Share-based Payment Arrangement [Abstract]

Schedule of Share-Based Compensation Expense

The following table summarizes the components of share-based compensation expense for the three months ended March 31, 2022 and 2021 (in thousands):

	Three Months Ended March 31,
	2022	2021
Research and development	$218	$96
General and administrative	542	501
Total share-based compensation expense	$760	$597

The following table summarizes the components of share-based compensation expense for the years ended December 31, 2021 and 2020 ($ in thousands):

	Year Ended December 31,
	2021	2020
Research and development	$760	$179
General and administrative	1,245	1,086
Total share-based compensation expense	$2,005	$1,265

	Stock Options	Restricted Stock Units	Restricted Stock
Unrecognized compensation cost	$757	$149	$546
Expected weighted-average period in years of compensation cost to be recognized	1.64	1.57	1.70

Schedule of Fair Value of Shares Vested and Weighted Average Estimated Fair Values of Shares Granted

Total fair value of shares vested and the weighted average estimated fair values of shares granted for the years ended December 31, 2021 and 2020 were as follows ($ in thousands):

Schedule of Assumptions in Calculating Fair Values of Stock Options

Total fair value of shares vested and the weighted average estimated fair values of shares granted for the three months ended March 31, 2022 and 2021 were as follows (in thousands):

The range of assumptions made in calculating the fair values of stock options was as follow:

	Stock Options
	Year Ended December 31,
	2021	2020
Expected term - minimum (in years)	6	6
Expected term - maximum (in years)	6	6
Expected volatility - minimum	79%	75%
Expected volatility - maximum	84%	79%
Weighted Average volatility	81%	75%
Expected dividend yield	—	—
Risk-free interest rate - minimum	0.63%	0.40%
Risk-free interest rate - maximum	1.16%	1.71%

Income Taxes (FY) (Tables)

12 Months Ended

Dec. 31, 2021

Income Tax Disclosure [Abstract]

Schedule of Provision for Income Taxes Based on Loss from Operations

The provision (benefit) for income taxes is based on loss from operations before provision for income taxes and noncontrolling interests as follows ($ in thousands):

	Years Ended December 31,
Pre-tax book income	2021	2020
United States	$(28,974)	$(19,013)
	$(28,974)	$(19,013)

Schedule of Benefit from Income Taxes

The provision (benefit) from income taxes was as follows ($ in thousands):

	Years Ended December 31,
	2021	2020
Current
U.S. Federal	$—	$—
State and local	—	—
	$—	$—

Deferred
U.S. Federal	$—	$—
State and local	(1,508)	(10,872)
	$(1,508)	$(10,872)

Total
U.S. Federal	$—	$—
State and local	(1,508)	(10,872)
	$(1,508)	$(10,872)

Schedule of Reconciliation of Effective Income Taxes

The provision (benefit) for income taxes is determined by applying the U.S. Federal statutory rate of 21% to income before income taxes, and the components are set forth below ($ in thousands):

	Years Ended December 31,
	2021	2020
U.S. Federal benefit at statutory rate	$(6,085)	$(3,993)
Permanent non deductible expenses for U.S. taxes	320	5
Change in state deferred	622	5,122
Return to actual	2,277	—
Other true ups	1,407	387
Section 382 NOL Limitation	35,438	—
Sale of New Jersey State NOLs	(1,508)	(10,872)
Valuation allowance for deferred tax assets	(33,979)	(1,521)
Tax provision (benefit)	$(1,508)	$(10,872)

Schedule of Components Deferred Income Taxes

Deferred income taxes at December 31, 2021 and 2020 consist of the following ($ in thousands):

	December 31,
	2021	2020
Deferred Tax Assets:
Accumulated net operating losses (tax effected)	$36,281	$68,286
Right of use liability	201	176
Share-based compensation	3,086	5,025
Intangibles	97	131
Accumulated depreciation	26	19
Accrued payroll	176	167
Other	526	526
Deferred tax assets	40,393	74,330

Deferred Tax Liabilities:
Right of use asset	$(204)	$(161)
Deferred tax liabilities	(204)	(161)
	40,189	74,169
Valuation allowance	(40,189)	(74,169)
Net deferred tax asset	$—	$—

Available-for-Sale-Securities (Q1) (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2022

Dec. 31, 2021

Debt Securities, Available-for-sale [Abstract]

Schedule of Available-for-sale Securities Reconciliation

The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):

	March 31, 2022				December 31, 2021
	Cost	Gross Unrealized Gains	Gross Unrealized Losses	Estimated Fair Value	Cost	Gross Unrealized Gains	Gross Unrealized Losses	Estimated Fair Value
Corporate debt securities	$62,770	$—	$(162)	$62,608	$53,135	$—	$(65)	$53,070
Money market funds	6,578	—	—	6,578	18,124	—	—	18,124
Municipal debt securities	17,267	—	(34)	17,233	20,263	—	(5)	20,258
Total	$86,615	$—	$(196)	$86,419	$91,522	$—	$(70)	$91,452

The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or debt marketable securities in the Company's Consolidated Balance Sheets (in thousands):

	December 31, 2021				December 31, 2020
	Cost	Gross Unrealized Gains	Gross Unrealized Losses	Estimated Fair Value	Cost	Gross Unrealized Gains	Gross Unrealized Losses	Estimated Fair Value
Corporate debt securities	$53,135	$—	$(65)	$53,070	$8,406	$—	$(7)	$8,399
Money market funds	18,124	—	—	18,124	7,591	—	—	7,591
Municipal debt securities	20,263	—	(5)	20,258	14,753	—	(6)	14,747
Total	$91,522	$—	$(70)	$91,452	$30,750	$—	$(13)	$30,737

Schedule of Marketable Securities

	March 31, 2022	December 31, 2021
Cash equivalents	$10,647	$21,129
Marketable securities	75,772	70,323
Total	$86,419	$91,452

Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale debt securities on the Company's Consolidated Balance Sheets (in thousands):

	December 31, 2021	December 31, 2020
Cash and cash equivalents	$21,129	$12,676
Marketable securities	70,323	18,061
Total	$91,452	$30,737

Investments Classified by Contractual Maturity Date

The following table summarizes our portfolio of available-for-sale securities by contractual maturity (in thousands):

	March 31, 2022
	Amortized Cost	Estimated Fair Value
Less than one year	$86,615	$86,419
Greater than one year		—
Total	$86,615	$86,419

The following table summarizes the Company's portfolio of available-for-sale securities by contractual maturity (in thousands):

	December 31, 2021		December 31, 2020
	Amortized Cost	Estimated Fair Value	Amortized Cost	Estimated Fair Value
Less than one year	$91,522	$91,452	$30,750	$30,737
Greater than one year	—	—	—	—
Total	$91,522	$91,452	$30,750	$30,737

Income (Loss) Per Share (Q1) (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2022

Dec. 31, 2021

Earnings Per Share [Abstract]

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

At March 31, 2022 and 2021, the Company excluded the following potentially dilutive securities (in thousands):

	March 31,
	2022	2021
Stock Options	2,640	1,022
Warrants	21,357	21,357
Restricted Stock Units	1,460	798

At December 31, 2021 and 2020, the Company excluded the following potentially dilutive securities (in thousands):

	December 31,
	2021	2020
Stock Options	2,132	964
Warrants	21,357	2,638
Restricted Stock Units	604	340

Fair Value Measurements (Q1) (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2022

Dec. 31, 2021

Fair Value Disclosures [Abstract]

Schedule of Assets Measured at Fair Value on Recurring Basis

	March 31, 2022				December 31, 2021
	Level 1	Level 2	Level 3	Total	Level 1	Level 2	Level 3	Total
Assets:
Marketable securities - available for sale	$—	$75,772	$—	$75,772	$—	$70,323	$—	$70,323
	$—	$75,772	$—	$75,772	$—	$70,323	$—	$70,323

The Company's financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2021 and December 31, 2020 were as follows (in thousands):

	December 31, 2021				December 31, 2020
	Level 1	Level 2	Level 3	Total	Level 1	Level 2	Level 3	Total
Assets:
Marketable securities - available for sale	$—	$70,323	$—	$70,323	$—	$18,061	$—	$18,061
	$—	$70,323	$—	$70,323	$—	$18,061	$—	$18,061

Accrued Liabilities (Q1) (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2022

Dec. 31, 2021

Accrued Liabilities [Abstract]

Schedule of Accrued Liabilities

Accrued liabilities as of March 31, 2022 and December 31, 2021 were as follows (in thousands):

	March 31, 2022	December 31, 2021
Salaries, employee benefits and related taxes	$1,005	$2,034
Operating lease liabilities — current	205	229
Other	894	326
Total	$2,104	$2,589

Accrued liabilities were as follow (in thousands):

	December 31,
	2021	2020
Salaries, employee benefits and related taxes	$2,034	$1,716
Operating lease liabilities - current	229	370
Other	326	400
	$2,589	$2,486

Operating Leases (Q1) (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2022

Dec. 31, 2021

Leases [Abstract]

Schedule of Operating Lease Liabilities and Right-of-Use Assets on Balance Sheet

Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet were as follows (in thousands):

	March 31, 2022	December 31, 2021
Right-of Use Assets:
Other assets	$667	$724
Total Right-of-Use Asset	$667	$724

Operating Lease Liabilities:
Accrued liabilities	$205	$229
Other long-term liabilities	421	485
Total Operating Lease Liabilities	$626	$714

Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet as follows (in thousands):

	December 31, 2021	December 31, 2020
Right-of Use Assets:
Other assets	$724	$574
Total Right-of-Use Asset	$724	$574

Operating Lease Liabilities:
Accrued liabilities	$229	$370
Other long-term liabilities	485	254
Total Operating Lease Liabilities	$714	$624

Schedule of Future Minimum Lease Payments Under Lease Agreements

Future minimum lease payments under the lease agreements as of March 31, 2022 were as follows (in thousands):

Years ended			Operating Leases
2022			181
2023			217
2024			190
2025			143
Total lease payments			731
Less: Amounts representing interest			(105)
Present value of lease liabilities			$626

Future minimum lease payments under the lease agreements as of December 31, 2021 were as follows (in thousands):

Years ended			Operating Leases
2022			$286
2023			217
2024			190
2025			143
Total lease payments			836
Less: Amounts representing interest			(122)
Present value of lease liabilities			$714

Stockholders' Equity (Q1) (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2022

Dec. 31, 2021

Equity [Abstract]

Schedule of Stock Option and Warrants Activity

The following table summarizes the activity for stock options and warrants for the three months ended March 31, 2022:

	Stock Options				Warrants
	Shares	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)	Shares	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)
Outstanding at December 31, 2021	2,131,849	$5.64	7.97	$—	21,356,600	$2.84	4.37	$—

Changes during the period:
Granted	540,600	0.91			—	—
Exercised	—	—			—	—
Forfeited	(9,565)	1.90			—	—
Expired	(23,275)	26.00			—	—
Outstanding at March 31, 2022	2,639,609	$4.51	7.83	$—	21,356,600	$2.84	4.13	$—
Vested at March 31, 2022 or expected to vest in the future	2,594,630	$4.57	7.80	$—	21,356,600	$2.84	4.13	$—
Vested at March 31, 2022	1,408,083	$7.36	6.41	$—	21,356,600	$2.84	4.13	$—

The following table summarizes the activity for stock options and warrants for the year ended December 31, 2021:

	Stock Options				Warrants
	Shares	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)	Shares	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)
Outstanding at December 31, 2020	963,700	$14.64	5.86	$—	2,638,355	$2.18	4.98	$—

Changes during the Year:
Granted	1,314,790	$1.32			19,519,393	$2.90
Exercised	(7,250)	$3.28		(3)	(801,148)	$2.19
Forfeited	(29,842)	$2.18			—	$—
Expired	(109,549)	$34.12			—	$—
Outstanding at December 31, 2021	2,131,849	$5.64	7.97	$—	21,356,600	$2.84	4.37	$—
Vested at December 31, 2021 or expected to vest in the future	2,120,643	$5.66	7.96	$—	21,356,600	$2.84	4.37	$—
Exercisable at December 31, 2021	1,122,783	$9.26	6.70	$—	21,356,600	$2.84	4.37	$—

Schedule of Restricted Stock Activity

During the three months ended March 31, 2022 and 2021, the Company issued restricted stock for services as follows ($ in thousands):

	Three Months Ended March 31,
	2022	2021
Number of restricted stock issued	1,061,175	300,450
Value of restricted stock issued	$973	$478

During the years ended December 31, 2021 and 2020, the Company issued restricted stock for services as follows ($ in thousands, except share data):

	2021	2020
Number of Restricted Stock Issued	612,950	156,184
Value of Restricted Stock Issued	$877.7	$512.3

Schedule of Restricted Stock Units Activity

During the three months ended March 31, 2022 and 2021, the Company issued restricted stock units for services as follows ($ in thousands, except share data):

	Three Months Ended March 31,
	2022	2021
Number of restricted stock units issued	1,379,860	458,245
Value of restricted stock units issued	$1,265	$729

Share-Based Compensation (Q1) (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2022

Dec. 31, 2021

Share-based Payment Arrangement [Abstract]

Schedule Share-based Compensation Expense

The following table summarizes the components of share-based compensation expense for the three months ended March 31, 2022 and 2021 (in thousands):

	Three Months Ended March 31,
	2022	2021
Research and development	$218	$96
General and administrative	542	501
Total share-based compensation expense	$760	$597

The following table summarizes the components of share-based compensation expense for the years ended December 31, 2021 and 2020 ($ in thousands):

	Year Ended December 31,
	2021	2020
Research and development	$760	$179
General and administrative	1,245	1,086
Total share-based compensation expense	$2,005	$1,265

	Stock Options	Restricted Stock Units	Restricted Stock
Unrecognized compensation cost	$757	$149	$546
Expected weighted-average period in years of compensation cost to be recognized	1.64	1.57	1.70

Schedule of Total Compensation Cost Related to Nonvested Awards

	Stock Options	Restricted Stock Units	Restricted Stock
Unrecognized compensation cost	$814	$444	$1,004
Expected weighted-average period in years of compensation cost to be recognized	1.77	0.96	2.25

Schedule of Fair Value of Share-based Compensation Awards

Total fair value of shares vested and the weighted average estimated fair values of shares granted for the three months ended March 31, 2022 and 2021 were as follows (in thousands):

The range of assumptions made in calculating the fair values of stock options was as follow:

	Stock Options
	Year Ended December 31,
	2021	2020
Expected term - minimum (in years)	6	6
Expected term - maximum (in years)	6	6
Expected volatility - minimum	79%	75%
Expected volatility - maximum	84%	79%
Weighted Average volatility	81%	75%
Expected dividend yield	—	—
Risk-free interest rate - minimum	0.63%	0.40%
Risk-free interest rate - maximum	1.16%	1.71%

The Business (FY) (Details) - USD ($) $ in Millions	Dec. 31, 2017	Feb. 28, 2017
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Grants awarded		$ 12.2
CLBS16 Treatment Of CMD
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Grants awarded	$ 1.9

Summary of Significant Accounting Policies (FY) (Details)	12 Months Ended
	Dec. 31, 2021
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Useful life (in years)	10 years
Computer equipment
Property, Plant and Equipment [Line Items]
Useful life (in years)	3 years
Software
Property, Plant and Equipment [Line Items]
Useful life (in years)	3 years

Available-for-Sale-Securities - Summary (FY) (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Debt Securities, Available-for-sale [Line Items]
Cost	$ 86,615	$ 91,522	$ 30,750
Gross Unrealized Gains	0	0	0
Gross Unrealized Losses	(196)	(70)	(13)
Estimated Fair Value	86,419	91,452	30,737
Corporate debt securities
Debt Securities, Available-for-sale [Line Items]
Cost	62,770	53,135	8,406
Gross Unrealized Gains	0	0	0
Gross Unrealized Losses	(162)	(65)	(7)
Estimated Fair Value	62,608	53,070	8,399
Money market funds
Debt Securities, Available-for-sale [Line Items]
Cost	6,578	18,124	7,591
Gross Unrealized Gains	0	0	0
Gross Unrealized Losses	0	0	0
Estimated Fair Value	6,578	18,124	7,591
Municipal debt securities
Debt Securities, Available-for-sale [Line Items]
Cost	17,267	20,263	14,753
Gross Unrealized Gains	0	0	0
Gross Unrealized Losses	(34)	(5)	(6)
Estimated Fair Value	$ 17,233	$ 20,258	$ 14,747

Available-for-Sale-Securities - Classification on Consolidated Balance Sheets (FY) (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Debt Securities, Available-for-sale [Line Items]
Available-for-sale debt securities	$ 86,419	$ 91,452	$ 30,737
Cash and cash equivalents
Debt Securities, Available-for-sale [Line Items]
Available-for-sale debt securities		21,129	12,676
Marketable securities
Debt Securities, Available-for-sale [Line Items]
Available-for-sale debt securities		$ 70,323	$ 18,061

Available-for-Sale-Securities - Contractual Maturities (FY) (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Amortized Cost
Less than one year		$ 91,522	$ 30,750
Greater than one year		0	0
Cost	$ 86,615	91,522	30,750
Estimated Fair Value
Less than one year		91,452	30,737
Greater than one year		0	0
Total estimated fair value	$ 86,419	$ 91,452	$ 30,737

Property and Equipment - Summary (FY) (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property and equipment, gross		$ 430	$ 370
Accumulated depreciation		(368)	(313)
Property and equipment, net	$ 55	62	57
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment, gross		26	26
Computer equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross		314	254
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross		$ 90	$ 90

Property and Equipment - Narrative (FY) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 0.1	$ 0.1

Loss Per Share (FY) (Details) - shares shares in Thousands	3 Months Ended		12 Months Ended
Loss Per Share (FY) (Details) - shares shares in Thousands	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of loss per share	2,640	1,022	2,132	964
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of loss per share	21,357	21,357	21,357	2,638
Restricted Stock Units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of loss per share	1,460	798	604	340

Fair Value Measurements (FY) (Details) - Recurring - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Assets:
Marketable securities - available for sale	$ 75,772	$ 70,323	$ 18,061
Assets, fair value disclosure	75,772	70,323	18,061
Level 1
Assets:
Marketable securities - available for sale	0	0	0
Assets, fair value disclosure	0	0	0
Level 2
Assets:
Marketable securities - available for sale	75,772	70,323	18,061
Assets, fair value disclosure	75,772	70,323	18,061
Level 3
Assets:
Marketable securities - available for sale	0	0	0
Assets, fair value disclosure	$ 0	$ 0	$ 0

Accrued Liabilities (FY) (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Accrued Liabilities [Abstract]
Salaries, employee benefits and related taxes		$ 2,034	$ 1,716
Operating lease liabilities - current	$ 205	229	370
Other	$ 894	326	400
Accrued liabilities		$ 2,589	$ 2,486

Operating Leases - Narrative (FY) (Details) - office	Mar. 31, 2022	Dec. 31, 2021
Leases [Abstract]
Number of offices under operating leases	2	2
Weighted average remaining lease term for operating leases (in years)	2 years 3 months 18 days	2 years 6 months
Weighted average discount rate for operating leases (percent)	9.625%	9.625%

Operating Leases - Balance Sheet Presentation (FY) (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Right-of Use Assets:
Right-of-use assets	$ 667	$ 724	$ 574
Right-of-use assets, balance sheet line item	Other assets	Other assets	Other assets
Operating Lease Liabilities:
Operating lease liabilities - current	$ 205	$ 229	$ 370
Operating lease liabilities, noncurrent	421	485	254
Operating lease liabilities	$ 626	$ 714	$ 624
Operating lease liabilities, current, balance sheet line item	Accrued liabilities	Accrued liabilities	Accrued liabilities
Operating lease liabilities, noncurrent, balance sheet line item	Other long-term liabilities	Other long-term liabilities	Other long-term liabilities

Operating Leases - Future Minimum Lease Payments Under Lease Agreements (FY) (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Future Minimum Lease Payments
2022	$ 217	$ 286
2023	190	217
2024	143	190
2025		143
Total lease payments	731	836
Less: Amounts representing interest	(105)	(122)
Present value of lease liabilities	$ 626	$ 714	$ 624

Stockholders' Equity - Equity Plan (FY) (Details)	12 Months Ended
Stockholders' Equity - Equity Plan (FY) (Details)	Dec. 31, 2021 USD ($) offering_period shares	Jun. 30, 2021 shares	Jun. 30, 2020 shares	May 31, 2017 shares	Jan. 01, 2013 shares
2018 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized for issuance		6,000,000	2,500,000
Number of shares available for future grant	5,585,661
2018 Plan \| Stock options \| Share-based award tranche one
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period (in years)	2 years
2018 Plan \| Stock options \| Share-based award tranche two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period (in years)	3 years
2018 Plan \| Stock options \| Share-based award tranche three
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period (in years)	10 years
ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of offering periods \| offering_period	2
Term of offering period	6 months
Maximum annual contribution per employee as percent of annual salary	15.00%
Maximum annual contribution per employee \| $	$ 25,000
Purchase price measurement as percent of closing price on enrollment date	85.00%
Purchase price measurement as percent of closing price on exercise date	85.00%
2012 ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized for issuance					50,000
2017 ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized for issuance				100,000
Amended 2017 ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized for issuance			500,000
Number of shares available for future grant	300,577
Shares issued under ESPP	47,132

Stockholders' Equity - Equity Issuances (FY) (Details) - USD ($)	1 Months Ended				3 Months Ended		12 Months Ended		36 Months Ended
	Feb. 28, 2021	Jan. 31, 2021	Mar. 31, 2019	Aug. 31, 2018	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Feb. 12, 2021	Jun. 04, 2021
Class of Stock [Line Items]
Net proceeds from issuance of capital stock	$ 65,000,000.0				$ 0	$ 85,457,000	$ 85,500,000	$ 18,728,000
Shares issued upon exercise of warrants		801,148
Net proceeds from warrant exercises		$ 1,800,000
Lincoln Park Agreement
Class of Stock [Line Items]
Aggregate offering amount authorized per agreement			$ 26,000,000.0
Commitment shares issued as consideration per agreement (shares)			181,510
Number of shares sold (shares)			250,000
Price of shares sold (in dollars per share)			$ 4.00
Gross price for stock transaction			$ 1,000,000
Term of agreement (in months)			36 months
Number of shares allowable to direct for Regular Purchase (shares)			100,000
Maximum obligation per directed purchase transaction for Regular Purchase			$ 2,500,000
Maximum shares allowed in Accelerated Purchase as percent of shares in Regular Purchase (percent)			300.00%
Maximum shares allowed in Accelerated Purchase as percent of shares traded during specified period (percent)			30.00%
Maximum beneficial ownership allowable per agreement (percent)			9.99%
Accelerated purchases specified floor price threshold for directed purchases							$ 1.00
H.C. Wainwright Sales Amended Agreement
Class of Stock [Line Items]
Aggregate offering amount authorized per agreement				$ 25,000,000.0
Commission on gross proceeds due to third party (percent)				3.00%
Stock issued (shares)							0		3,784,912
Net proceeds from issuance of capital stock									$ 9,500,000
ATM Agreement
Class of Stock [Line Items]
Aggregate offering amount authorized per agreement										$ 50,000,000.0
Stock issued (shares)					0		0
Institutional Purchase Agreement
Class of Stock [Line Items]
Number of shares sold (shares)	24,906,134
Price of shares sold (in dollars per share)	$ 2.45
Number of shares called by warrants issued	12,453,067
Warrant exercise price (in dollars per share)	$ 2.90
Warrants expiration term	5 years
Additional Purchase Agreement
Class of Stock [Line Items]
Number of shares sold (shares)	1,632,652
Price of shares sold (in dollars per share)	$ 2.45
Number of shares called by warrants issued	816,326
Warrant exercise price (in dollars per share)	$ 2.90
Warrants expiration term	5 years
January 2021 Private Placement
Class of Stock [Line Items]
Number of shares sold (shares)		12,500,000
Price of shares sold (in dollars per share)		$ 2.00
Net proceeds from issuance of capital stock		$ 25,000,000.0
Number of shares called by warrants issued		6,250,000
Warrant exercise price (in dollars per share)		$ 2.90
Warrants expiration term		5 years 6 months
Number of shares per each warrant		1

Stockholders' Equity - Stock Options and Warrants (FY) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Stock Options, Shares
Options, outstanding, beginning balance (in shares)	2,131,849	963,700
Granted (shares)		1,314,790
Exercised (shares)	0	(7,250)
Forfeited (shares)	(9,565)	(29,842)
Expired (shares)	(23,275)	(109,549)
Options, outstanding, ending balance (in shares)	2,639,609	2,131,849	963,700
Vested or expected to vest (shares)	2,594,630	2,120,643
Exercisable (shares)	1,408,083	1,122,783
Stock Options, Weighted Average Exercise Price
Options, outstanding. beginning balance (in dollars per share)	$ 5.64	$ 14.64
Granted (in dollars per share)	0.91	1.32
Exercised (in dollars per share)	0	3.28
Forfeited (in dollars per share)	1.90	2.18
Expired (in dollars per share)	26.00	34.12
Options, outstanding, ending balance (in dollars per share)	4.51	5.64	$ 14.64
Vested or expected to vest (in dollars per share)	4.57	5.66
Exercisable (in dollars per share)	$ 7.36	$ 9.26
Stock Options, Weighted Average Contractual Term and Intrinsic Value
Options outstanding, weighted average remaining contractual term (in years)	7 years 9 months 29 days	7 years 11 months 19 days	5 years 10 months 9 days
Options vested or expected to vest, weighted average remaining contractual term (in years)	7 years 9 months 18 days	7 years 11 months 15 days
Options exercisable, weighted average remaining contractual term (in years)		6 years 8 months 12 days
Options outstanding, aggregate intrinsic value	$ 0	$ 0	$ 0
Options exercised, aggregate intrinsic value		(3)
Options vested or expected to vest, aggregate intrinsic value	0	0
Options exercisable, aggregate intrinsic value	$ 0	$ 0
Warrants, Shares
Warrants outstanding, beginning balance (in shares)	21,356,600	2,638,355
Warrants granted (shares)	0	19,519,393
Warrants exercised (shares)	0	(801,148)
Warrants forfeited (shares)	0	0
Warrants expired (shares)	0	0
Warrants outstanding, ending balance (in shares)	21,356,600	21,356,600	2,638,355
Warrants vested or expected to vest (shares)	21,356,600	21,356,600
Warrants exercisable (shares)	21,356,600	21,356,600
Warrants, Weighted Average Exercise Price
Warrants outstanding, beginning balance (in dollars per share)	$ 2.84	$ 2.18
Warrants granted (in dollars per share)	0	2.90
Warrants exercised (in dollars per share)	0	2.19
Warrants forfeited (in dollars per share)	0	0
Warrants expired (in dollars per share)	0	0
Warrants outstanding, ending balance (in dollars per share)	2.84	2.84	$ 2.18
Warrants vested or expected to vest (in dollars per share)	2.84	2.84
Warrants exercisable (in dollars per share)	$ 2.84	$ 2.84
Warrants, Weighted Average Contractual Term and Intrinsic Value
Warrants outstanding, weighted average remaining contractual term (in years)	4 years 1 month 17 days	4 years 4 months 13 days	4 years 11 months 23 days
Warrants vested or expected to vest, weighted average remaining contractual term (in years)	4 years 1 month 17 days	4 years 4 months 13 days
Warrants exercisable, weighted average remaining contractual term (in years)	4 years 1 month 17 days	4 years 4 months 13 days
Warrants outstanding, aggregate intrinsic value	$ 0	$ 0	$ 0
Warrants vested or expected to vest, aggregate intrinsic value	0	0
Warrants exercisable, aggregate intrinsic value	$ 0	$ 0

Stockholders' Equity - Restricted Stock and Restricted Stock Units (FY) (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Restricted Stock
Restricted Stock and Restricted Stock Units
Number of shares issued (shares)	1,061,175	300,450	612,950	156,184
Value of shares issued	$ 973,000	$ 478,000	$ 877,700	$ 512,300
Weighted average estimated fair value	$ 0.92	$ 1.59	$ 1.43	$ 3.28
Restricted Stock \| Minimum
Restricted Stock and Restricted Stock Units
Vesting terms (in years)	1 year		1 year
Restricted Stock \| Maximum
Restricted Stock and Restricted Stock Units
Vesting terms (in years)	4 years		4 years
Restricted Stock Units
Restricted Stock and Restricted Stock Units
Number of shares issued (shares)	1,379,860	458,245	458,245	325,853
Value of shares issued	$ 1,265,000	$ 729,000	$ 728,600	$ 863,000.0
Weighted average estimated fair value			$ 1.59	$ 2.65
Vesting terms (in years)	1 year		1 year

Share-Based Compensation - Share-Based Compensation Expense (FY) (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation [Line Items]
Share-based compensation expense	$ 760	$ 597	$ 2,005	$ 1,265
Research and development
Share-based Compensation [Line Items]
Share-based compensation expense	218	96	760	179
General and administrative
Share-based Compensation [Line Items]
Share-based compensation expense	$ 542	$ 501	$ 1,245	$ 1,086

Share-Based Compensation - Compensation Cost Not Yet Recognized (FY) (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 814	$ 757
Expected weighted-average period in years of compensation cost to be recognized	1 year 9 months 7 days	1 year 7 months 20 days
Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 444	$ 149
Expected weighted-average period in years of compensation cost to be recognized	11 months 15 days	1 year 6 months 25 days
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 1,004	$ 546
Expected weighted-average period in years of compensation cost to be recognized	2 years 3 months	1 year 8 months 12 days

Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (FY) (Details) - Stock Options - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total fair value of shares vested	$ 377	$ 397	$ 757	$ 536
Weighted average estimated fair value of shares granted (in dollars per share)	$ 0.62	$ 1.08	$ 0.91	$ 2.11

Share-Based Compensation - Valuation Assumptions (FY) (Details) - Stock Options	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Valuation Assumptions
Expected volatility - minimum	79.00%	75.00%
Expected volatility - maximum	84.00%	79.00%
Weighted Average volatility	81.00%	75.00%
Expected dividend yield	0.00%	0.00%
Risk-free interest rate - minimum	0.63%	0.40%
Risk-free interest rate - maximum	1.16%	1.71%
Minimum
Valuation Assumptions
Expected term (in years)	6 years	6 years
Maximum
Valuation Assumptions
Expected term (in years)	6 years	6 years

Research Funding (FY) (Details) - USD ($) $ in Thousands	1 Months Ended					12 Months Ended		41 Months Ended
Research Funding (FY) (Details) - USD ($) $ in Thousands	Sep. 30, 2020	May 31, 2019	Mar. 31, 2018	Dec. 31, 2017	May 31, 2017	Dec. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Feb. 28, 2017
Research and Development [Abstract]
Grants awarded									$ 12,200
Total funding amount awarded									$ 8,600
Funding of grant award					$ 5,700			$ 8,200
Milestone payment received on grant award				$ 1,900
Progress payment received on grant award			$ 300
Progress payment amortized to related research and development over estimated award period	$ 46	$ 200
Amortization of accrued grant funding to offset expense						$ 0	$ 1,600

Income Taxes - Loss from Operations Before Provision for Income Taxes (FY) (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Pre-tax book income - United States			$ (28,974)	$ (19,013)
Pre-tax book income	$ (6,705)	$ (8,063)	$ (28,974)	$ (19,013)

- Definition

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

Income Taxes - Components of Benefit from Income Taxes (FY) (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Current
U.S. Federal			$ 0	$ 0
State and local			0	0
Total current income tax provision (benefit)			0	0
Deferred
U.S. Federal			0	0
State and local			(1,508)	(10,872)
Total deferred income tax provision (benefit)			(1,508)	(10,872)
Total
U.S. Federal			0	0
State and local			(1,508)	(10,872)
Tax provision (benefit)	$ (2,479)	$ 0	$ (1,508)	$ (10,872)

Income Taxes - Effective Income Tax Reconciliation (FY) (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Effective Income Tax Rate Reconciliation, Amount [Abstract]
U.S. Federal benefit at statutory rate			$ (6,085)	$ (3,993)
Permanent non deductible expenses for U.S. taxes			320	5
Change in state deferred			622	5,122
Return to actual			2,277	0
Other true ups			1,407	387
Section 382 NOL Limitation			35,438	0
Sale of New Jersey State NOLs			(1,508)	(10,872)
Valuation allowance for deferred tax assets			(33,979)	(1,521)
Tax provision (benefit)	$ (2,479)	$ 0	$ (1,508)	$ (10,872)

Income Taxes - Components of Deferred Income Taxes (FY) (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Deferred Tax Assets:
Accumulated net operating losses (tax effected)	$ 36,281	$ 68,286
Right of use liability	201	176
Share-based compensation	3,086	5,025
Intangibles	97	131
Accumulated depreciation	26	19
Accrued payroll	176	167
Other	526	526
Deferred tax assets	40,393	74,330
Deferred Tax Liabilities:
Right of use asset	(204)	(161)
Deferred tax liabilities	(204)	(161)
Net deferred tax assets and liabilities	40,189	74,169
Valuation allowance	(40,189)	(74,169)
Net deferred tax asset	$ 0	$ 0

Income Taxes - Narrative (FY) (Details) - USD ($) $ in Millions			12 Months Ended
	Feb. 22, 2022	Apr. 12, 2021	Dec. 31, 2021	Dec. 31, 2020
Income Taxes [Line Items]
U.S. federal corporate income tax rate (percent)			21.00%
Possible additional NOLs for five years resulting from Net Unrealized Built-in Gain rules			$ 1.1
Proceeds from sale of NOLs	$ 2.3	$ 1.4
Proceeds from sale of NOLs, gross	2.5	1.5
Loss on sale of NOLs	$ 0.1	$ 0.1
Federal
Income Taxes [Line Items]
Net operating loss carryforwards, prior to write down			281.0
Net operating loss carryforwards			112.0	$ 264.0
Write down of NOLs set to expire unutilized			169.0
State \| New Jersey
Income Taxes [Line Items]
Net operating loss carryforwards			97.0	99.0
State \| California
Income Taxes [Line Items]
Net operating loss carryforwards			70.0	70.0
State \| New York
Income Taxes [Line Items]
Net operating loss carryforwards			$ 13.0	$ 13.0

The Business (Q1) (Details) - USD ($) $ in Thousands	Apr. 26, 2022	Dec. 31, 2017	Feb. 28, 2017
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Grants awarded			$ 12,200
Subsequent event \| Merger Agreement \| Cend
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Expected post-merger ownership in Company by Cend stockholders (percent)	50.00%
Expected post-merger ownership in Company by Company stockholders (percent)	50.00%
Transaction expenses threshold for allocation	$ 250
CLBS16 Treatment of CMD
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Grants awarded		$ 1,900

Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Q1) (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Debt Securities, Available-for-sale [Line Items]
Cost	$ 86,615	$ 91,522	$ 30,750
Gross Unrealized Gains	0	0	0
Gross Unrealized Losses	(196)	(70)	(13)
Estimated Fair Value	86,419	91,452	30,737
Corporate debt securities
Debt Securities, Available-for-sale [Line Items]
Cost	62,770	53,135	8,406
Gross Unrealized Gains	0	0	0
Gross Unrealized Losses	(162)	(65)	(7)
Estimated Fair Value	62,608	53,070	8,399
Money market funds
Debt Securities, Available-for-sale [Line Items]
Cost	6,578	18,124	7,591
Gross Unrealized Gains	0	0	0
Gross Unrealized Losses	0	0	0
Estimated Fair Value	6,578	18,124	7,591
Municipal debt securities
Debt Securities, Available-for-sale [Line Items]
Cost	17,267	20,263	14,753
Gross Unrealized Gains	0	0	0
Gross Unrealized Losses	(34)	(5)	(6)
Estimated Fair Value	$ 17,233	$ 20,258	$ 14,747

Available-for-Sale-Securities - Classification of Available-for-Sale Securities (Q1) (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Debt Securities, Available-for-sale [Abstract]
Cash equivalents	$ 10,647	$ 21,129
Marketable securities	75,772	70,323	$ 18,061
Total	$ 86,419	$ 91,452

Available-for-Sale-Securities - Available-for-Sale Securities by Contractual Maturity (Q1) (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Amortized Cost
Less than one year	$ 86,615
Cost	86,615	$ 91,522	$ 30,750
Estimated Fair Value
Less than one year	86,419
Greater than one year	0
Total estimated fair value	$ 86,419	$ 91,452	$ 30,737

Income (Loss) Per Share (Q1) (Details) - shares shares in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	2,640	1,022	2,132	964
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	21,357	21,357	21,357	2,638
Restricted Stock Units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	1,460	798	604	340

Fair Value Measurements (Q1) (Details) - Recurring - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities - available for sale	$ 75,772	$ 70,323	$ 18,061
Assets, fair value disclosure	75,772	70,323	18,061
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities - available for sale	0	0	0
Assets, fair value disclosure	0	0	0
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities - available for sale	75,772	70,323	18,061
Assets, fair value disclosure	75,772	70,323	18,061
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities - available for sale	0	0	0
Assets, fair value disclosure	$ 0	$ 0	$ 0

Accrued Liabilities (Q1) (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Accrued Liabilities [Abstract]
Salaries, employee benefits and related taxes	$ 1,005	$ 2,034
Operating lease liabilities - current	205	229	$ 370
Other	894	326	400
Total accrued liabilities	$ 2,104	$ 2,589	$ 2,486

Operating Leases - Narrative (Q1) (Details) - office	Mar. 31, 2022	Dec. 31, 2021
Leases [Abstract]
Number of offices under operating leases	2	2
Weighted average remaining lease term for operating leases (in years)	2 years 3 months 18 days	2 years 6 months
Weighted average discount rate for operating leases (percent)	9.625%	9.625%

Operating Leases - Balance Sheet Presentation (Q1) (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Right-of Use Assets:
Right-of-use assets	$ 667	$ 724	$ 574
Right-of-use assets, balance sheet line item	Other assets	Other assets	Other assets
Operating Lease Liabilities:
Operating lease liabilities, current	$ 205	$ 229	$ 370
Operating lease liabilities, noncurrent	421	485	254
Operating lease liabilities	$ 626	$ 714	$ 624
Operating lease liabilities, current, balance sheet line item	Accrued liabilities	Accrued liabilities	Accrued liabilities
Operating lease liabilities, noncurrent, balance sheet line item	Other long-term liabilities	Other long-term liabilities	Other long-term liabilities

Operating Leases - Future Minimum Lease Payments (Q1) (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Finance Minimum Lease Payments
2022	$ 181
2023	217	$ 286
2024	190	217
2025	143	190
Total lease payments	731	836
Less: Amounts representing interest	(105)	(122)
Present value of lease liabilities	$ 626	$ 714	$ 624

Stockholders' Equity - Equity Issuances (Q1) (Details) - USD ($)	1 Months Ended	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2022	Dec. 31, 2021	Jun. 04, 2021
Lincoln Park Agreement
Class of Stock [Line Items]
Aggregate offering amount authorized per agreement	$ 26,000,000.0
Commitment shares issued as consideration per agreement (in shares)	181,510
Number of shares sold (in shares)	250,000
Price of shares sold (in dollars per share)	$ 4.00
Gross price for stock transaction	$ 1,000,000
Term of agreement (in months)	36 months
Number of shares allowable to direct for Regular Purchase (in shares)	100,000
Maximum obligation per directed purchase transaction for Regular Purchase	$ 2,500,000
Maximum shares allowed in Accelerated Purchase as percent of shares In Regular Purchase (percent)	300.00%
Maximum shares allowed in Accelerated Purchase as percent of shares traded during specified period (percent)	30.00%
Maximum beneficial ownership allowable per agreement (percent)	9.99%
Accelerated purchases specified floor price threshold for directed purchases			$ 1.00
ATM Agreement
Class of Stock [Line Items]
Aggregate offering amount authorized per agreement				$ 50,000,000.0
Stock issued (shares)		0	0

Stockholders' Equity - Stock Options and Warrants (Q1) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Stock Options, Shares
Options, outstanding, beginning balance (in shares)	2,131,849	963,700
Options, Granted (in shares)	540,600
Options, Exercised (in shares)	0	(7,250)
Options, Forfeited (in shares)	(9,565)	(29,842)
Options, Expired (in shares)	(23,275)	(109,549)
Options, outstanding, ending balance (in shares)	2,639,609	2,131,849	963,700
Options, Vested and expected to vest (in shares)	2,594,630	2,120,643
Options, Vested (in shares)	1,408,083	1,122,783
Stock Options, Weighted Average Exercise Price
Options, outstanding. beginning balance (in dollars per share)	$ 5.64	$ 14.64
Options, Granted (in dollars per share)	0.91	1.32
Options, Exercised (in dollars per share)	0	3.28
Options, Forfeited (in dollars per share)	1.90	2.18
Options, Expired (in dollars per share)	26.00	34.12
Options, outstanding, ending balance (in dollars per share)	4.51	5.64	$ 14.64
Options, Vested and expected to vest (in dollars per share)	4.57	5.66
Options, Vested (in dollars per share)	$ 7.36	$ 9.26
Stock Options, Weighted Average Contractual Term and Intrinsic Value
Options, Outstanding, Weighted Average Remaining Contractual Term	7 years 9 months 29 days	7 years 11 months 19 days	5 years 10 months 9 days
Options, Vested and expected to vest, Weighted Average Remaining Contractual Term	7 years 9 months 18 days	7 years 11 months 15 days
Options, Vested, Weighted Average Remaining Contractual Term	6 years 4 months 28 days
Options, Outstanding, Aggregate Intrinsic Value	$ 0	$ 0	$ 0
Options, Vested and expected to vest, Aggregate Intrinsic Value	0	0
Options, Vested, Aggregate Intrinsic Value	$ 0	$ 0
Warrants, Shares
Warrants outstanding, beginning balance (in shares)	21,356,600	2,638,355
Warrants, Granted (in shares)	0	19,519,393
Warrants, Exercised (in shares)	0	(801,148)
Warrants, Forfeited (in shares)	0	0
Warrants, Expired (in shares)	0	0
Warrants outstanding, ending balance (in shares)	21,356,600	21,356,600	2,638,355
Warrants, Vested and expected to vest (in shares)	21,356,600	21,356,600
Warrants, Vested (in shares)	21,356,600	21,356,600
Warrants, Weighted Average Exercise Price
Warrants outstanding, beginning balance (in dollars per share)	$ 2.84	$ 2.18
Warrants, Granted (in dollars per share)	0	2.90
Warrants, Exercised (in dollars per share)	0	2.19
Warrants, Forfeited (in dollars per share)	0	0
Warrants, Expired (in dollars per share)	0	0
Warrants outstanding, ending balance (in dollars per share)	2.84	2.84	$ 2.18
Weighted Average Exercise Price, Warrants Vested And Expected To Vest	2.84	2.84
Warrants, Vested, Weighted Average Exercise Price (in dollars per share)	$ 2.84	$ 2.84
Warrants, Weighted Average Contractual Term and Intrinsic Value
Warrants, Outstanding, Weighted Average Remaining Contractual Term	4 years 1 month 17 days	4 years 4 months 13 days	4 years 11 months 23 days
Warrants, Vested and expected to vest, Weighted Average Remaining Contractual Term	4 years 1 month 17 days	4 years 4 months 13 days
Warrants, Vested, Weighted Average Remaining Contractual Term	4 years 1 month 17 days	4 years 4 months 13 days
Warrants Outstanding, Aggregate Intrinsic Value	$ 0	$ 0	$ 0
Warrants, Vested and expected to vest, Aggregate Intrinsic Value	0	0
Warrants, Vested, Aggregate Intrinsic Value	$ 0	$ 0

Stockholders' Equity - Restricted Stock and Restricted Stock Units (Q1) (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares issued	1,061,175	300,450	612,950	156,184
Value of shares issued	$ 973,000	$ 478,000	$ 877,700	$ 512,300
Weighted average estimated fair value	$ 0.92	$ 1.59	$ 1.43	$ 3.28
Restricted Stock \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting terms (years)	1 year		1 year
Restricted Stock \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting terms (years)	4 years		4 years
Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares issued	1,379,860	458,245	458,245	325,853
Value of shares issued	$ 1,265,000	$ 729,000	$ 728,600	$ 863,000.0
Weighted average estimated fair value			$ 1.59	$ 2.65
Vesting terms (years)	1 year		1 year

Share-Based Compensation - Share-Based Compensation Expense (Q1) (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense	$ 760	$ 597	$ 2,005	$ 1,265
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense	218	96	760	179
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense	$ 542	$ 501	$ 1,245	$ 1,086

Share-Based Compensation - Compensation Cost Not Yet Recognized (Q1) (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 814	$ 757
Expected weighted-average period in years of compensation cost to be recognized	1 year 9 months 7 days	1 year 7 months 20 days
Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 444	$ 149
Expected weighted-average period in years of compensation cost to be recognized	11 months 15 days	1 year 6 months 25 days
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 1,004	$ 546
Expected weighted-average period in years of compensation cost to be recognized	2 years 3 months	1 year 8 months 12 days

Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Q1) (Details) - Stock Options - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total fair value of shares vested	$ 377	$ 397	$ 757	$ 536
Weighted average estimated fair value of shares granted	$ 0.62	$ 1.08	$ 0.91	$ 2.11

Income Taxes (Q1) (Details) - USD ($) $ in Millions	Feb. 22, 2022	Apr. 12, 2021	Dec. 31, 2021	Dec. 31, 2020
Operating Loss Carryforwards [Line Items]
Possible additional NOLs for five years resulting from Net Unrealized Built-in Gain rules			$ 1.1
Proceeds from sale of NOLs, gross	$ 2.5	$ 1.5
Net proceeds from sale of NOLs	2.3	1.4
Loss on sale of NOLs	$ 0.1	$ 0.1
Federal
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards, prior to write down			281.0
Net operating loss carryforwards			112.0	$ 264.0
Write down of NOLs set to expire unutilized			169.0
State \| New Jersey
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards			97.0	99.0
State \| California
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards			70.0	70.0
State \| New York
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards			$ 13.0	$ 13.0

Subsequent Events (Q1) (Details) - USD ($) $ / shares in Units, $ in Thousands	Apr. 26, 2022	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Subsequent Event [Line Items]
Preferred stock, par value (in usd per share)		$ 0.01	$ 0.01	$ 0.01
Subsequent event \| Merger Agreement \| Cend
Subsequent Event [Line Items]
Expected post-merger ownership in Company by Cend stockholders (percent)	50.00%
Expected post-merger ownership in Company by Company stockholders (percent)	50.00%
Transaction expenses threshold for allocation	$ 250
Minimum net cash threshold at closing per agreement	64,900
Potential termination fee payable	1,000
Potential termination fee receivable	4,000
Potential expense reimbursement per agreement	$ 1,000
Subsequent event \| Cend Purchase Agreement
Subsequent Event [Line Items]
Series D original issue price (in usd per share)	$ 8.8057
Aggregate price	$ 10,000
Pre-Equity Offering Value After Conversion	$ 250,000
Subsequent event \| Cend Purchase Agreement \| Cend Series D preferred stock
Subsequent Event [Line Items]
Number of shares purchased	1,135,628
Preferred stock, par value (in usd per share)	$ 0.00001
Subsequent event \| Cend Purchase Agreement \| Cend
Subsequent Event [Line Items]
Potential gross proceeds	$ 50,000